<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MDM</journal-id>
<journal-id journal-id-type="hwp">spmdm</journal-id>
<journal-id journal-id-type="nlm-ta">Med Decis Making</journal-id>
<journal-title>Medical Decision Making</journal-title>
<issn pub-type="ppub">0272-989X</issn>
<issn pub-type="epub">1552-681X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0272989X12453504</article-id>
<article-id pub-id-type="publisher-id">10.1177_0272989X12453504</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Choice of a Noninformative Prior on Between-Study Variance Strongly Affects Predictions of Future Treatment Effect</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Gajic-Veljanoski</surname><given-names>Olga</given-names></name>
<degrees>MD, MSc</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Cheung</surname><given-names>Angela M.</given-names></name>
<degrees>MD, PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Bayoumi</surname><given-names>Ahmed M.</given-names></name>
<degrees>MD, MSc</degrees>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Tomlinson</surname><given-names>George</given-names></name>
<degrees>PhD</degrees>
</contrib>
</contrib-group>
<aff id="aff1-0272989X12453504">Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada (OG-V, AMC, AMB, GT)</aff>
<aff id="aff2-0272989X12453504">Osteoporosis Program, University Health Network, Toronto, Toronto, Ontario, Canada (OG-V, AMC)</aff>
<aff id="aff3-0272989X12453504">Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada (GT)</aff>
<aff id="aff4-0272989X12453504">Department of Medicine, University of Toronto, Toronto, Ontario, Canada (AMC, AMB, GT)</aff>
<aff id="aff5-0272989X12453504">Centre for Research on Inner City Health, The Keenan Research Centre in the Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, Ontario, Canada (AMB)</aff>
<author-notes>
<corresp id="corresp1-0272989X12453504">George Tomlinson: University Health Network–Toronto General Hospital, 200 Elizabeth Street, Eaton North Wing 13 EN-238, Toronto, ON M5G 2C4, Canada; e-mail: <email>george.tomlinson@utoronto.ca</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>33</volume>
<issue>3</issue>
<issue-title>Special Issue: Health Technology Assessment to Inform Policy</issue-title>
<fpage>356</fpage>
<lpage>368</lpage>
<history>
<date date-type="received">
<day>12</day>
<month>9</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>2</day>
<month>5</month>
<year>2012</year>
</date>
</history>
<abstract>
<p><bold>Purpose.</bold> Bayesian random-effects meta-analyses require the analyst to specify the prior distribution for between-study variance of the treatment effect. We assessed the sensitivity of prediction and other outputs of the meta-analysis to the choice of this prior. <bold>Methods.</bold> We reanalyzed 7 published meta-analyses (5–14 trials) with rare (event rates &lt;5%), moderate (15%–50%), and frequent binary outcomes (&gt;50%). We examined 10 noninformative priors: inverse gamma on between-study variance (<italic>τ</italic><sup>2</sup>), 2 uniforms on each of the between-study standard deviation (<italic>τ</italic>) and <italic>τ</italic><sup>2</sup>, uniform shrinkage on <italic>τ</italic><sup>2</sup>, DuMouchel shrinkage on τ, half-normal on <italic>τ</italic><sup>2</sup>, and half-normal priors on τ with large and small variances. For each analysis, we calculated the posterior distributions for τ, the population treatment effect in current studies, and the predicted treatment effect in a future study. We assessed goodness of fit using total residual deviance, the deviance information criterion, and predictive deviance (by cross-validations). <bold>Results.</bold> According to total residual deviance, the best-fitting priors were uniform on <italic>τ</italic><sup>2</sup>. According to predictive deviance, half-normal on <italic>τ</italic><sup>2</sup> and the shrinkage priors were optimal. Across analyses with the 10 priors, there were no important differences in the posteriors for the population treatment effect, but there were substantial differences in the posteriors for τ and predictions. The priors that fitted best according to predictive deviance resulted in less uncertainty around predictions of future treatment effect. <bold>Conclusions.</bold> In this sample of Bayesian meta-analyses with binary outcomes, the choice of noninformative prior for between-study variance affected model fit and the predictions of future treatment effect. When the predictive distribution is of interest, we highly recommend examination of multiple prior distributions for between-study variance, especially the half-normal on <italic>τ</italic><sup>2</sup> and the shrinkage priors.</p>
</abstract>
<kwd-group>
<kwd>noninformative priors</kwd>
<kwd>between-study variance</kwd>
<kwd>goodness-of-fit</kwd>
<kwd>predictions</kwd>
<kwd>random-effects meta-analysis</kwd>
<kwd>Bayesian methods</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Bayesian models combine study information, which we will call current evidence, with previous information to produce new knowledge.<sup><xref ref-type="bibr" rid="bibr1-0272989X12453504">1</xref></sup> In Bayesian terms, information from previous study is called a prior, current evidence is called a likelihood, and new knowledge is called a posterior. A posterior is produced by updating priors with current evidence,<sup><xref ref-type="bibr" rid="bibr1-0272989X12453504">1</xref></sup> typically through random-effects meta-analysis, which accounts for variability in observed treatment effects by modeling both within and between-study variance.<sup><xref ref-type="bibr" rid="bibr2-0272989X12453504">2</xref><xref ref-type="bibr" rid="bibr3-0272989X12453504"/>–<xref ref-type="bibr" rid="bibr4-0272989X12453504">4</xref></sup> Bayesian random-effects models are typically used to compute the posterior distribution of the treatment effect but can be easily extended to predict the treatment effect in a future study.<sup><xref ref-type="bibr" rid="bibr3-0272989X12453504">3</xref></sup> Predictive distributions are important but most often an underappreciated aspect of Bayesian meta-analysis. Predictive intervals account for the uncertainty around the population mean treatment effect and the uncertainty around the estimate of between-study heterogeneity.<sup><xref ref-type="bibr" rid="bibr3-0272989X12453504">3</xref>,<xref ref-type="bibr" rid="bibr5-0272989X12453504">5</xref></sup> The 95% prediction intervals convey confidence or certainty in the true treatment effect in at least 95% of individual trial settings.<sup><xref ref-type="bibr" rid="bibr3-0272989X12453504">3</xref>,<xref ref-type="bibr" rid="bibr5-0272989X12453504">5</xref></sup> Predictive distributions can be used for sample size calculations,<sup><xref ref-type="bibr" rid="bibr1-0272989X12453504">1</xref></sup> for decision modeling,<sup><xref ref-type="bibr" rid="bibr1-0272989X12453504">1</xref>,<xref ref-type="bibr" rid="bibr6-0272989X12453504">6</xref>,<xref ref-type="bibr" rid="bibr7-0272989X12453504">7</xref></sup> and for prioritizing investment decisions regarding future research.<sup><xref ref-type="bibr" rid="bibr7-0272989X12453504">7</xref><xref ref-type="bibr" rid="bibr8-0272989X12453504"/><xref ref-type="bibr" rid="bibr9-0272989X12453504"/><xref ref-type="bibr" rid="bibr10-0272989X12453504"/>–<xref ref-type="bibr" rid="bibr11-0272989X12453504">11</xref></sup></p>
<p>Bayesian random-effects meta-analysis requires the analyst to specify 2 key prior distributions: one for the mean of the treatment effect and another for the corresponding between-study variance. Changing distributional assumptions around priors on the mean treatment effect from informative to uninformative can substantially influence the posterior distributions of both population and future treatment effects.<sup><xref ref-type="bibr" rid="bibr1-0272989X12453504">1</xref>,<xref ref-type="bibr" rid="bibr12-0272989X12453504">12</xref></sup> Previous research has suggested that appropriate modeling of between-study variance is similarly important.<sup><xref ref-type="bibr" rid="bibr3-0272989X12453504">3</xref></sup> Noninformative (vague) priors are considered more objective as they let the “data to dominate”<sup><xref ref-type="bibr" rid="bibr13-0272989X12453504">13</xref></sup>; consequently, they are suggested for modeling between-study variance.<sup><xref ref-type="bibr" rid="bibr1-0272989X12453504">1</xref></sup> However, Lambert and others<sup><xref ref-type="bibr" rid="bibr14-0272989X12453504">14</xref></sup> performed a simulation study including 13 vague priors on between-study variance and demonstrated that assuming different vague priors for between-study variance resulted in different posterior estimates of the mean treatment effect and the between-study standard deviation. Gelman<sup><xref ref-type="bibr" rid="bibr15-0272989X12453504">15</xref></sup> found that noninformative priors on between-study variance used in studies with big sample sizes should be different from those used in studies with small sample sizes. Pullenayegum<sup><xref ref-type="bibr" rid="bibr16-0272989X12453504">16</xref></sup> used data from several Cochrane meta-analyses to estimate priors on between-study variance of the treatment effect and showed that the posteriors of population treatment effects and model fit (by deviance information criterion) varied across the inverse gamma, gamma, log-normal, and uniform prior distributions. However, to our knowledge, no study has examined the influence of priors for between-study heterogeneity on the predictive distribution of Bayesian meta-analysis.</p>
<p>Given the recently recognized importance of predictions in Bayesian evidence synthesis and economic evaluations,<sup><xref ref-type="bibr" rid="bibr3-0272989X12453504">3</xref>,<xref ref-type="bibr" rid="bibr6-0272989X12453504">6</xref>,<xref ref-type="bibr" rid="bibr7-0272989X12453504">7</xref>,<xref ref-type="bibr" rid="bibr10-0272989X12453504">10</xref>,<xref ref-type="bibr" rid="bibr17-0272989X12453504">17</xref></sup> we conducted an empirical study to extend our understanding of the effect of prior distributions on between-study variance on the prediction and other major outcomes of Bayesian random-effects meta-analyses of binary data. Our primary objective was to evaluate 10 proposed noninformative prior distributions by examining model goodness of fit, posterior distributions of the treatment effect in current and future studies, and the posterior distribution of between-study variance. Our secondary objective was to compare the performance of these priors across meta-analyses with varying degrees of heterogeneity and disease frequency.</p>
<sec id="section1-0272989X12453504" sec-type="methods">
<title>Methods</title>
<p>We used Bayesian hierarchical random-effects models to reanalyze the data from 7 meta-analyses. We examined meta-analyses that assessed binary outcomes and included analyses that spanned a range in terms of the number of pooled studies (5–14) and the degree of observed heterogeneity (I<sup>2</sup> statistic = 21%–84% and between-study variance calculated by the method of moments = 0.01–0.53; <xref ref-type="table" rid="table1-0272989X12453504">Table 1</xref>). The selected meta-analyses were relatively small in size; hence, they provided a solid ground for our research on priors for between-study variance because the true value of between-study variance and the uncertainty around it are difficult to estimate by classical approaches, particularly in small meta-analyses.<sup><xref ref-type="bibr" rid="bibr3-0272989X12453504">3</xref>,<xref ref-type="bibr" rid="bibr18-0272989X12453504">18</xref><xref ref-type="bibr" rid="bibr19-0272989X12453504"/>–<xref ref-type="bibr" rid="bibr20-0272989X12453504">20</xref></sup> The interventions studied included vitamin D for preventing hip fractures among older people,<sup><xref ref-type="bibr" rid="bibr21-0272989X12453504">21</xref>,<xref ref-type="bibr" rid="bibr22-0272989X12453504">22</xref></sup> antibiotics for preventing rheumatic fever or resolving sore throat symptoms among patients with a sore throat,<sup><xref ref-type="bibr" rid="bibr23-0272989X12453504">23</xref></sup> vitamin D for preventing falls among older people,<sup><xref ref-type="bibr" rid="bibr24-0272989X12453504">24</xref></sup> and oral estrogen, with or without progesterone, for preventing hot flushes among peri- and postmenopausal women.<sup><xref ref-type="bibr" rid="bibr25-0272989X12453504">25</xref></sup> We classified outcomes as rare (event rates in control groups &lt;5%, hip fracture and acute rheumatic fever), moderately common (event rates of 5% to 50%, falls and symptoms of sore throat at day 6–8), or frequent (event rates &gt;50%, hot flushes and symptoms of sore throat at day 3; <xref ref-type="table" rid="table1-0272989X12453504">Table 1</xref>).</p>
<table-wrap id="table1-0272989X12453504" position="float">
<label>Table 1</label>
<caption>
<p>Description of Meta-Analyses Used in Bayesian Random-Effects Models</p>
</caption>
<graphic alternate-form-of="table1-0272989X12453504" xlink:href="10.1177_0272989X12453504-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th/>
<th/>
<th/>
<th align="center" colspan="2">Between-Study Heterogeneity<hr/></th>
<th/>
</tr>
<tr>
<th align="left">Data Source (Reference)</th>
<th align="center">Outcome</th>
<th align="center">Frequency of the Outcome<sup><xref ref-type="table-fn" rid="table-fn2-0272989X12453504">a</xref></sup> (%)</th>
<th align="center">Intervention</th>
<th align="center">Number of Trials</th>
<th align="center">I<sup>2</sup> Statistic (%)</th>
<th align="center">Variance<sup><xref ref-type="table-fn" rid="table-fn3-0272989X12453504">b</xref></sup></th>
<th align="center">Pooled Odds Ratio<sup><xref ref-type="table-fn" rid="table-fn3-0272989X12453504">b</xref></sup> (95% CI)</th>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td>Spinks A (23)</td>
<td>Acute rheumatic fever</td>
<td>2</td>
<td>Antibiotics</td>
<td>14</td>
<td>21</td>
<td>0.07</td>
<td>0.25 (0.14, 0.45)</td>
</tr>
<tr>
<td>Avenell A (21)</td>
<td>Hip fracture</td>
<td>1</td>
<td>Vitamin D</td>
<td>6</td>
<td>28</td>
<td>0.04</td>
<td>0.79 (0.62, 0.99)</td>
</tr>
<tr>
<td>Bischoff-Ferrari H (22)</td>
<td>Hip fracture</td>
<td>3</td>
<td>Vitamin D</td>
<td>8</td>
<td>45</td>
<td>0.02</td>
<td>0.91 (0.78, 1.05)</td>
</tr>
<tr>
<td>Cranney A (24)</td>
<td>Falls</td>
<td>40</td>
<td>Vitamin D</td>
<td>13</td>
<td>23</td>
<td>0.01</td>
<td>0.89 (0.81, 0.99)</td>
</tr>
<tr>
<td>Spinks A (23)</td>
<td>Sore throat symptom day 6–8</td>
<td>18</td>
<td>Antibiotics</td>
<td>13</td>
<td>71</td>
<td>0.45</td>
<td>0.56 (0.45, 0.70)</td>
</tr>
<tr>
<td>MacLennan A (25)</td>
<td>Hot flushes</td>
<td>66</td>
<td>HRT</td>
<td>5</td>
<td>34</td>
<td>0.25</td>
<td>0.11 (0.05, 0.24)</td>
</tr>
<tr>
<td>Spinks A (23)</td>
<td>Sore throat symptom day 3</td>
<td>67</td>
<td>Antibiotics</td>
<td>12</td>
<td>84</td>
<td>0.53</td>
<td>0.34 (0.21, 0.55)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0272989X12453504">
<p>Note: CI = confidence interval; HRT = hormone replacement therapy.</p>
</fn>
<fn id="table-fn2-0272989X12453504">
<label>a.</label>
<p>Rates of events (%) in control groups.</p>
</fn>
<fn id="table-fn3-0272989X12453504">
<label>b.</label>
<p>Estimated by the classical random-effects meta-analysis method.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>We examined 10 candidate noninformative priors for the parameter representing between-study heterogeneity (<xref ref-type="table" rid="table2-0272989X12453504">Table 2</xref>).<sup><xref ref-type="bibr" rid="bibr14-0272989X12453504">14</xref>,<xref ref-type="bibr" rid="bibr15-0272989X12453504">15</xref>,<xref ref-type="bibr" rid="bibr26-0272989X12453504">26</xref></sup> We focused on the between-study variance of the natural log of the odds ratio, which we called τ<sup>2</sup>, or the corresponding between-study standard deviation, which we called τ. <xref ref-type="fig" rid="fig1-0272989X12453504">Figure 1</xref> presents the probability density functions of the examined prior distributions on the standard deviation (τ) scale, plotted over the range 0 to 4. Although all distributions are ostensibly noninformative about the prior distribution, each represents a different belief about between-study heterogeneity. For example, the uniform shrinkage probability density function on τ<sup>2</sup> has a peak for very low values of τ and steadily declines with increasing values of τ; as such, it favors low between-study variability.<sup><xref ref-type="bibr" rid="bibr26-0272989X12453504">26</xref></sup> When viewed as a distribution for τ, the uniform probability density function on τ<sup>2</sup> has increasing density over its whole range but drops to zero outside the range. By contrast, the uniform probability density function for τ puts the same weight on all values of τ in its range; thus, it specifies a maximum possible value but indicates no prior preference among allowable values for the standard deviation between studies.<sup><xref ref-type="bibr" rid="bibr26-0272989X12453504">26</xref></sup></p>
<table-wrap id="table2-0272989X12453504" position="float">
<label>Table 2</label>
<caption>
<p>Description of 10 Noninformative Priors on the Between-Study Heterogeneity Parameter (τ or τ<sup>2</sup>)</p>
</caption>
<graphic alternate-form-of="table2-0272989X12453504" xlink:href="10.1177_0272989X12453504-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Noninformative prior</th>
<th align="center">Distribution</th>
<th align="center">WinBUGS Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inverse gamma (gamma on 1/τ<sup>2</sup>) (26)</td>
<td>τ<sup>−2</sup>~ Gamma (0.01, 0.01)</td>
<td>inv.tau.sqrd ~ dgamma(0.01, 0.01)<break/>tau.sqrd &lt;- 1 / inv.tau.sqrd<break/>tau &lt;- sqrt(tau.sqrd)</td>
</tr>
<tr>
<td>Uniform on between-study variance (τ<sup>2</sup>) (26)</td>
<td>τ<sup>2</sup>~ U (0,k)<break/>k = 3 or 9</td>
<td>tau.sqrd ~ dunif(0, k)<break/>tau &lt;- sqrt(tau.sqrd)<break/>inv.tau.sqrd &lt;- 1 / tau.sqrd</td>
</tr>
<tr>
<td>Uniform on between-study standard deviation (τ) (26)</td>
<td>τ ~ U (0,k)<break/>k = <inline-formula id="inline-formula1-0272989X12453504"><mml:math display="inline" id="math1-0272989X12453504"><mml:mrow><mml:msqrt><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msqrt></mml:mrow></mml:math></inline-formula> or 3</td>
<td>tau ~ dunif(0, k)<break/>tau.sqrd &lt;- tau * tau<break/>inv.tau.sqrd &lt;- 1 / tau.sqrd</td>
</tr>
<tr>
<td>Uniform shrinkage on τ<sup>2</sup> (equivalent to a uniform prior on the average shrinkage - B0) (26)</td>
<td>τ<sup>2</sup> ~ s0<sup>2</sup>/(s0<sup>2</sup>+τ<sup>2</sup>)<sup>2</sup><break/>s0<sup>-2</sup> = (1/n)*Σ s<sub>n</sub><sup>-2</sup></td>
<td>B0 ~ dunif(0, 1)<break/>tau.sqrd &lt;- s0.sqrd * (1 - B0)/B0<break/>tau &lt;- sqrt(tau.sqrd)<break/>inv.tau.sqrd &lt;- 1 / tau.sqrd</td>
</tr>
<tr>
<td>DuMouchel prior on τ (equivalent to a uniform shrinkage prior - D0 on τ) (26)</td>
<td>τ ~ s0 / (s0 +τ)<sup>2</sup><break/>or<break/>τ<sup>2</sup> ~ s0<sup>2</sup>/(s0<sup>2</sup>+τ<sup>2</sup>)<sup>2</sup></td>
<td>D0 ~ dunif(0, 1)<break/>tau &lt;- sqrt(s0.sqrd) *(1 -D0)/D0<break/>tau.sqrd &lt;- tau * tau<break/>inv.tau.sqrd &lt;- 1 / tau.sqrd</td>
</tr>
<tr>
<td>Half-normal (HN) on τ<sup>2</sup> (26)</td>
<td>τ<sup>2</sup> ~ N(0, p0), τ<sup>2</sup> &gt; 0</td>
<td>p0 &lt;- phi(0.75) / s0.sqrd<break/>tau.sqrd ~ dnorm(0, p0)I(0, )<break/>tau &lt;- sqrt(tau.sqrd)<break/>inv.tau.sqrd &lt;- 1 / tau.sqrd</td>
</tr>
<tr>
<td>HN on τ, big between-study variance =100 (14)</td>
<td>τ ~ N(0, 0.01), τ &gt; 0</td>
<td>tau~ dnorm(0, 0.01)I(0, )<break/>tau.sqrd &lt;- tau * tau<break/>inv.tau.sqrd &lt;- 1 / tau.sqrd</td>
</tr>
<tr>
<td>HN on τ, small between-study variance = 1 (14)</td>
<td>τ ~ N(0,1), τ &gt; 0</td>
<td>tau~ dnorm(0, 1)I(0, )<break/>tau.sqrd &lt;- tau * tau<break/>inv.tau.sqrd &lt;- 1 / tau.sqrd</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0272989X12453504">
<p>Note: n = number of studies; s<sub>n</sub><sup>2</sup> = within-study variance; s0<sup>2</sup> = the harmonic mean of the s<sub>n</sub><sup>2</sup>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig1-0272989X12453504" position="float">
<label>Figure 1</label>
<caption>
<p>Eight prior probability density functions for the between-study heterogeneity parameter, plotted for values of the standard deviation between 0 and 4. Plots of 2 other priors, <italic>τ</italic><sup>2</sup>~U(0,3) and <italic>τ</italic>~U(0, <inline-formula id="inline-formula2-0272989X12453504"><mml:math display="inline" id="math2-0272989X12453504"><mml:mrow><mml:msqrt><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msqrt></mml:mrow></mml:math></inline-formula>), are omitted.</p>
</caption>
<graphic xlink:href="10.1177_0272989X12453504-fig1.tif"/>
</fig>
<p>For each meta-analysis, we calculated the posterior distributions for the population treatment effect, the predicted treatment effect in a future study, and the between-study standard deviation using each of the 10 noninformative priors on between-study variability and the uniform prior (from −4 to 4) on the mean treatment effect. Samples from the posterior distributions of each parameter were obtained by the Markov chain Monte Carlo method.<sup><xref ref-type="bibr" rid="bibr27-0272989X12453504">27</xref></sup> The 2.5th and 97.5th percentiles were used to create central 95% credible intervals (95% CrI).<sup><xref ref-type="bibr" rid="bibr1-0272989X12453504">1</xref></sup></p>
<p>We reanalyzed the meta-analyses using a hierarchical random-effects model<sup><xref ref-type="bibr" rid="bibr3-0272989X12453504">3</xref></sup> with the following structure. We assumed that the data in the control and treatment arms of the trials were sampled from a binomial distribution:</p>
<disp-formula id="disp-formula1-0272989X12453504">
<mml:math display="block" id="math3-0272989X12453504">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mtext>r</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>~</mml:mo>
<mml:mtext>Binom</mml:mtext>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>p</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>n</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-0272989X12453504" xlink:href="10.1177_0272989X12453504-eq1.tif"/>
</disp-formula>
<p>where r<sub><italic>i</italic></sub> denotes the number of patients with the outcome, p<sub><italic>i</italic></sub> denotes the probability of the outcome, and n<sub><italic>i</italic></sub> denotes the total number of patients in that arm (<italic>i</italic>). We modeled treatment effects using logistic regression</p>
<disp-formula id="disp-formula2-0272989X12453504">
<mml:math display="block" id="math4-0272989X12453504">
<mml:mrow>
<mml:mtext>logit</mml:mtext>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>p</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>α</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mtext>s</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msup>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mtext>β</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mtext>s</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:mo>*</mml:mo>
</mml:mrow>
</mml:msup>
<mml:msub>
<mml:mrow>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>s</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>3</mml:mn>
<mml:mo>…</mml:mo>
<mml:mtext>S</mml:mtext>
<mml:mo>;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>T</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-0272989X12453504" xlink:href="10.1177_0272989X12453504-eq2.tif"/>
</disp-formula>
<p>where α<sub>s(<italic>i</italic>)</sub> is the log-odds in the control group of study s<sub><italic>i</italic></sub>, β<sub>s(<italic>i</italic>)</sub> is the log-odds ratio for the treatment group in study s<sub><italic>i</italic></sub>, and T<sub>(<italic>i</italic>)</sub> is an indicator variable representing the active treatment arm or the placebo. The log-odds in the control group α<sub>s(<italic>i</italic>)</sub> were assumed to be independent, whereas the log-odds ratios for treatment β<sub>s(<italic>i</italic>)</sub> were treated as exchangeable, modeled as random effects, and were sampled from a normal distribution with mean <italic>d</italic> and between-study variance<sup><xref ref-type="bibr" rid="bibr3-0272989X12453504">3</xref></sup>τ<sup>2</sup>:</p>
<disp-formula id="disp-formula3-0272989X12453504">
<mml:math display="block" id="math5-0272989X12453504">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>β</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mtext>s</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>~</mml:mo>
<mml:mtext>N</mml:mtext>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mtext>d</mml:mtext>
<mml:mo>,</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>τ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msup>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula3-0272989X12453504" xlink:href="10.1177_0272989X12453504-eq3.tif"/>
</disp-formula>
<p>We sampled predictions of the true treatment effect in a future study (denoted as β<sub>new</sub>) from the posteriors of the random-effects distribution of the treatment effects<sup><xref ref-type="bibr" rid="bibr3-0272989X12453504">3</xref></sup>:</p>
<disp-formula id="disp-formula4-0272989X12453504">
<mml:math display="block" id="math6-0272989X12453504">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>β</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mtext>new</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>~</mml:mo>
<mml:mtext>N</mml:mtext>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mtext>d</mml:mtext>
<mml:mo>,</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>τ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msup>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula4-0272989X12453504" xlink:href="10.1177_0272989X12453504-eq4.tif"/>
</disp-formula>
<p>We used 3 methods to assess the goodness of fit of the models. First, we used total residual deviance (RD) to identify the best- and the worst-fitting priors for each meta-analysis.<sup><xref ref-type="bibr" rid="bibr27-0272989X12453504">27</xref>,<xref ref-type="bibr" rid="bibr28-0272989X12453504">28</xref></sup> Second, we calculated the deviance information criterion (DIC), which penalizes the deviance by the effective number of parameters reflecting model complexity. We assumed that differences &gt;5 in DIC or RD represented important differences in model fit.<sup><xref ref-type="bibr" rid="bibr29-0272989X12453504">29</xref></sup></p>
<p>Third, we assessed goodness of fit by examining the ability of the models to make predictions.<sup><xref ref-type="bibr" rid="bibr30-0272989X12453504">30</xref><xref ref-type="bibr" rid="bibr31-0272989X12453504"/>–<xref ref-type="bibr" rid="bibr32-0272989X12453504">32</xref></sup> To evaluate predictions of future treatment effects, we carried out a cross-validation exercise wherein one study was excluded from the meta-analysis and that study’s observed outcomes were compared with the meta-analysis’s prediction based on the remaining studies. These steps were then repeated for each study in the meta-analysis to calculate a goodness-of-fit measure of a predictive model, which we called the total predictive deviance (PD). To compute PD in our binomial model, we first omitted data from the treatment arm <italic>i</italic> and refitted the meta-analysis model to generate a predicted log-odds ratio (<inline-formula id="inline-formula3-0272989X12453504"><mml:math display="inline" id="math7-0272989X12453504"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>new</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>), sampled from the posterior distribution of the treatment effect (in <xref ref-type="disp-formula" rid="disp-formula4-0272989X12453504">equation 4</xref>) without arm <italic>i</italic>. We calculated a predicted probability of the outcome in the omitted treatment arm <inline-formula id="inline-formula4-0272989X12453504"><mml:math display="inline" id="math8-0272989X12453504"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> using the relationship</p>
<disp-formula id="disp-formula5-0272989X12453504">
<mml:math display="block" id="math9-0272989X12453504">
<mml:mrow>
<mml:mtext>logit</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mtext>s</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>β</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>new</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msubsup>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula5-0272989X12453504" xlink:href="10.1177_0272989X12453504-eq5.tif"/>
</disp-formula>
<p>We calculated <inline-formula id="inline-formula5-0272989X12453504"><mml:math display="inline" id="math10-0272989X12453504"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>—the expected number of patients with the outcome—as a product of <inline-formula id="inline-formula6-0272989X12453504"><mml:math display="inline" id="math11-0272989X12453504"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and n<sub><italic>i</italic></sub> and used it to compute predictive deviance contributions for binomial models as described in Appendix 1. The predictive deviance was computed from the residual contribution of both arms of the omitted study (Appendix 2). The total predictive deviance (PD) was calculated as the sum of the individual predictive deviance contributions across all leave-one-out model fits.</p>
<p>We also used the values of <inline-formula id="inline-formula7-0272989X12453504"><mml:math display="inline" id="math12-0272989X12453504"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> to identify outlying trials. For each predicted <inline-formula id="inline-formula8-0272989X12453504"><mml:math display="inline" id="math13-0272989X12453504"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, we predicted the number of patients with the outcome <inline-formula id="inline-formula9-0272989X12453504"><mml:math display="inline" id="math14-0272989X12453504"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and compared it to the observed count <inline-formula id="inline-formula10-0272989X12453504"><mml:math display="inline" id="math15-0272989X12453504"><mml:mrow><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>. We generated a Bayesian <italic>P</italic> value by calculating the probability that the predicted count was larger than the observed count and defined outlier trials as those with <italic>P</italic> values ≤10% or ≥90%.<sup><xref ref-type="bibr" rid="bibr27-0272989X12453504">27</xref>,<xref ref-type="bibr" rid="bibr28-0272989X12453504">28</xref>,<xref ref-type="bibr" rid="bibr33-0272989X12453504">33</xref>,<xref ref-type="bibr" rid="bibr34-0272989X12453504">34</xref></sup> We examined whether the rank order of models as assessed by the PD criterion changed after the exclusion of outlying trials.</p>
<p>The analyses were done in WinBUGS 1.4.3 (Imperial College and MRC, UK, 2007)<sup><xref ref-type="bibr" rid="bibr35-0272989X12453504">35</xref></sup> and R 2.11.1 (The R Foundation for Statistical Computing, Austria, 2010). Our Bayesian analyses were all done to the same standard: We ran 3 Markov chains starting at dispersed sets of initial values for a total of 300 000 iterations, of which the first 30 000 were discarded. Convergence of the chains was checked by Brooks-Gelman-Rubin plots and the Gelman-Rubin statistic.<sup><xref ref-type="bibr" rid="bibr36-0272989X12453504">36</xref></sup> The chains were considered to have converged when the Gelman-Rubin statistic reached 1.<sup><xref ref-type="bibr" rid="bibr36-0272989X12453504">36</xref></sup> We performed classical meta-analyses and calculated I<sup>2</sup> statistics associated with between-study heterogeneity<sup><xref ref-type="bibr" rid="bibr2-0272989X12453504">2</xref>,<xref ref-type="bibr" rid="bibr4-0272989X12453504">4</xref></sup> and the approximation of likelihoods for between-study standard deviation (by the method of moments<sup><xref ref-type="bibr" rid="bibr2-0272989X12453504">2</xref></sup>) using RevMan 5 (the Cochrane Collaboration, the Nordic Cochrane Centre, Copenhagen, Denmark, 2008). Details of the calculations of the binomial RD and PD as well as WinBUGS programs are presented in the Appendix.</p>
</sec>
<sec id="section2-0272989X12453504" sec-type="results">
<title>Results</title>
<sec id="section3-0272989X12453504">
<title>Goodness of Fit of Priors on τ<sup>2</sup></title>
<sec id="section4-0272989X12453504">
<title>Residual deviance</title>
<p>In all meta-analyses, models using a uniform prior on τ<sup>2</sup> were the best fitting, as assessed by the lowest total RD (<xref ref-type="table" rid="table3-0272989X12453504">Table 3</xref>). This result was consistent across analyses with varying event frequency, number of pooled studies, or between-study heterogeneity. In most cases, models using the inverse gamma prior were the worst fitting. Nevertheless, in all meta-analyses, the estimates of RD for the best- and the worst-fitting priors differed by only 2 units (less than the value of 5, which we considered important<sup><xref ref-type="bibr" rid="bibr29-0272989X12453504">29</xref></sup>). When we used DIC as the criterion for model fit, models using a uniform on τ or on τ<sup>2</sup> were the best fitting; the differences between the highest and the lowest DIC across the 10 considered priors were similarly small (<xref ref-type="table" rid="table3-0272989X12453504">Table 3</xref>).</p>
<table-wrap id="table3-0272989X12453504" position="float">
<label>Table 3</label>
<caption>
<p>Goodness of Fit of Noninformative Priors on τ or τ<sup>2</sup> (Ranked by PD) and the Results of 7 Meta-Analyses by the Prior and Frequency of Outcome</p>
</caption>
<graphic alternate-form-of="table3-0272989X12453504" xlink:href="10.1177_0272989X12453504-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="center"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Between-Study</th>
<th/>
<th/>
<th/>
<th/>
<th align="center" colspan="6">Posterior Outputs of Bayesian Meta-Analysis<sup><xref ref-type="table-fn" rid="table-fn6-0272989X12453504">a</xref></sup><hr/></th>
</tr>
<tr>
<th/>
<th align="center">Heterogeneity,</th>
<th/>
<th align="center" colspan="3">Goodness-of-Fit Measures<hr/></th>
<th align="center" colspan="2">Population OR<hr/></th>
<th align="center" colspan="2">Future Study OR<hr/></th>
<th align="center" colspan="2">τ<hr/></th>
</tr>
<tr>
<th align="left">Meta-Analysis</th>
<th align="center">I<sup>2</sup> (%), SD<sup>a</sup>
</th>
<th align="center">Priors on τ/τ<sup>2</sup>
</th>
<th align="center">RD</th>
<th align="center">DIC (pD)</th>
<th align="center">PD</th>
<th align="center">Mean/Median</th>
<th align="center">95% CrI</th>
<th align="center">Mean/Median</th>
<th align="center">95% CrI</th>
<th align="center">Mean/Median</th>
<th align="center">95%CrI</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="12">Rare outcomes</td>
</tr>
<tr>
<td rowspan="2"> Acute rheumatic fever (n = 14)</td>
<td align="center" rowspan="2">21%<break/>0.26</td>
<td>HN on τ, variance = 1</td>
<td>28.7</td>
<td>82.5 (9.7)</td>
<td>34.1</td>
<td>0.16/0.16</td>
<td>0.05, 0.32</td>
<td>0.22/0.16</td>
<td>0.02, 0.74</td>
<td>0.65/0.59</td>
<td>0.05, 1.60</td>
</tr>
<tr>
<td>HN on τ<sup>2</sup>
</td>
<td>28.2</td>
<td>82.1 (9.8)</td>
<td>36.5</td>
<td>0.16/0.15</td>
<td>0.05, 0.32</td>
<td>0.22/0.15</td>
<td>0.02, 0.83</td>
<td>0.75/0.74</td>
<td>0.21, 1.38</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ, U~(0,<inline-formula id="inline-formula11-0272989X12453504">
<mml:math display="inline" id="math16-0272989X12453504">
<mml:mrow>
<mml:msqrt>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
</mml:msqrt>
</mml:mrow>
</mml:math>
</inline-formula>)</td>
<td>28.6</td>
<td>78.5 (10.0)</td>
<td>38.0</td>
<td>0.16/0.15</td>
<td>0.04, 0.31</td>
<td>0.23/0.16</td>
<td>0.01, 0.88</td>
<td>0.75/0.71</td>
<td>0.06, 1.61</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform shrinkage on τ<sup>2</sup>
</td>
<td>28.4</td>
<td>82.3 (9.8)</td>
<td>39.6</td>
<td>0.16/0.15</td>
<td>0.05, 0.32</td>
<td>0.26/0.16</td>
<td>0.02, 0.81</td>
<td>0.72/0.65</td>
<td>0.15, 1.69</td>
</tr>
<tr>
<td/>
<td/>
<td>DuMouchel on τ</td>
<td>29.1</td>
<td>82.8 (9.6)</td>
<td>39.8</td>
<td>0.17/0.17</td>
<td>0.05, 0.31</td>
<td>0.25/0.17</td>
<td>0.02, 0.70</td>
<td>0.58/0.49</td>
<td>0.02, 1.71</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ<sup>2</sup> U~(0,3)</td>
<td>28.0</td>
<td>82.5 (10.5)</td>
<td>47.4</td>
<td>0.14/0.13</td>
<td>0.04, 0.32</td>
<td>0.25/0.14</td>
<td>0.01, 1.16</td>
<td>0.98/0.97</td>
<td>0.24, 1.68</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ U~(0,3)</td>
<td>28.4</td>
<td>82.9 (10.4)</td>
<td>64.1</td>
<td>0.15/0.15</td>
<td>0.03, 0.31</td>
<td>0.31/0.15</td>
<td>0.01, 1.10</td>
<td>0.87/0.76</td>
<td>0.07, 2.32</td>
</tr>
<tr>
<td/>
<td/>
<td>Inverse gamma</td>
<td>29.6</td>
<td>82.9 (9.2)</td>
<td>64.2</td>
<td>0.18/0.17</td>
<td>0.05, 0.31</td>
<td>0.29/0.18</td>
<td>0.02, 0.60</td>
<td>0.48/0.36</td>
<td>0.03, 1.66</td>
</tr>
<tr>
<td/>
<td/>
<td>HN on τ, variance = 100</td>
<td>28.5</td>
<td>82.8 (10.4)</td>
<td>77.4</td>
<td>0.15/0.15</td>
<td>0.03, 0.32</td>
<td>37.65/0.16</td>
<td>0.01, 1.15</td>
<td>0.89/0.76</td>
<td>0.06, 2.50</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ<sup>2</sup> U~(0,9)</td>
<td>27.9</td>
<td>78.9 (11.0)</td>
<td>82.0</td>
<td>0.13/0.12</td>
<td>0.03, 0.31</td>
<td>0.45/0.13</td>
<td>0.00, 1.89</td>
<td>1.24/1.13</td>
<td>0.29, 2.69</td>
</tr>
<tr>
<td colspan="9"><hr/></td>
</tr>
<tr>
<td> Hip fracture (n = 6)</td>
<td align="center" rowspan="2">28%<break/>0.20</td>
<td>DuMouchel on τ</td>
<td>14.1</td>
<td>80.2 (7.8)</td>
<td>28.9</td>
<td>0.76/0.76</td>
<td>0.57, 1.01</td>
<td>0.79/0.75</td>
<td>0.44, 1.32</td>
<td>0.16/0.11</td>
<td>0.00, 0.59</td>
</tr>
<tr>
<td/>
<td>Uniform shrinkage on ττ<sup>2</sup>
</td>
<td>13.6</td>
<td>80.0 (8.1)</td>
<td>30.0</td>
<td>0.77/0.76</td>
<td>0.56, 1.03</td>
<td>0.79/0.76</td>
<td>0.42, 1.38</td>
<td>0.20/0.17</td>
<td>0.03, 0.55</td>
</tr>
<tr>
<td/>
<td/>
<td>HN on τ<sup>2</sup>
</td>
<td>12.9</td>
<td>80.1 (8.8)</td>
<td>37.2</td>
<td>0.78/0.76</td>
<td>0.51, 1.14</td>
<td>0.83/0.76</td>
<td>0.32, 1.81</td>
<td>0.33/0.32</td>
<td>0.07, 0.66</td>
</tr>
<tr>
<td/>
<td/>
<td>HN on τ, variance = 1</td>
<td>13.4</td>
<td>77.7 (8.6)</td>
<td>43.4</td>
<td>0.77/0.76</td>
<td>0.50, 1.15</td>
<td>0.94/0.76</td>
<td>0.30, 1.91</td>
<td>0.30/0.24</td>
<td>0.01, 0.97</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ U~(0,<inline-formula id="inline-formula12-0272989X12453504">
<mml:math display="inline" id="math17-0272989X12453504">
<mml:mrow>
<mml:msqrt>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
</mml:msqrt>
</mml:mrow>
</mml:math>
</inline-formula>)</td>
<td>13.3</td>
<td>76.3 (8.8)</td>
<td>50.1</td>
<td>0.78/0.76</td>
<td>0.46, 1.20</td>
<td>0.88/0.76</td>
<td>0.26, 2.12</td>
<td>0.33/0.25</td>
<td>0.01, 1.16</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ U~(0,3)</td>
<td>13.3</td>
<td>80.4 (8.8)</td>
<td>62.1</td>
<td>0.78/0.76</td>
<td>0.46, 1.23</td>
<td>1.01/0.76</td>
<td>0.24, 2.30</td>
<td>0.36/0.26</td>
<td>0.01, 1.32</td>
</tr>
<tr>
<td/>
<td/>
<td>HN on τ, variance = 100</td>
<td>13.3</td>
<td>79.1 (8.8)</td>
<td>72.4</td>
<td>0.78/0.76</td>
<td>0.45, 1.23</td>
<td align="center">&gt;100/0.76</td>
<td>0.23, 2.32</td>
<td>0.36/0.26</td>
<td>0.01, 1.40</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ<sup>2</sup> U~(0,3)</td>
<td>12.7</td>
<td>80.5 (9.5)</td>
<td>82.7</td>
<td>0.79/0.76</td>
<td>0.36, 1.47</td>
<td>1.10/0.76</td>
<td>0.14, 3.91</td>
<td>0.59/0.49</td>
<td>0.09, 1.54</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ<sup>2</sup> U~(0,9)</td>
<td>12.6</td>
<td>76.5 (9.7)</td>
<td>122.4</td>
<td>0.81/0.76</td>
<td>0.29, 1.64</td>
<td>2.26/0.75</td>
<td>0.09, 5.56</td>
<td>0.70/0.52</td>
<td>0.10, 2.30</td>
</tr>
<tr>
<td/>
<td/>
<td>Inverse gamma</td>
<td>13.9</td>
<td>80.1 (8.5)</td>
<td>132.2</td>
<td>0.77/0.76</td>
<td>0.56, 1.04</td>
<td>1.02/0.76</td>
<td>0.41, 1.42</td>
<td>0.19/0.13</td>
<td>0.03, 0.71</td>
</tr>
<tr>
<td colspan="9"><hr/></td>
</tr>
<tr>
<td> Hip fracture (n = 8)</td>
<td align="center" rowspan="2">45%<break/>0.14</td>
<td>DuMouchel on τ</td>
<td>17.6</td>
<td>129.1 (11.9)</td>
<td>40.5</td>
<td>0.89/0.88</td>
<td>0.75, 1.05</td>
<td>0.90/0.88</td>
<td>0.61, 1.30</td>
<td>0.13/0.11</td>
<td>0.01, 0.36</td>
</tr>
<tr>
<td/>
<td>Uniform shrinkage on τ<sup>2</sup>
</td>
<td>16.7</td>
<td>128.4 (12.2)</td>
<td>43.3</td>
<td>0.89/0.89</td>
<td>0.75, 1.06</td>
<td>0.90/0.89</td>
<td>0.60, 1.32</td>
<td>0.15/0.14</td>
<td>0.03, 0.34</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ U~(0,<inline-formula id="inline-formula13-0272989X12453504">
<mml:math display="inline" id="math18-0272989X12453504">
<mml:mrow>
<mml:msqrt>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
</mml:msqrt>
</mml:mrow>
</mml:math>
</inline-formula>)</td>
<td>16.3</td>
<td>124.7 (12.9)</td>
<td>50.1</td>
<td>0.89/0.89</td>
<td>0.72, 1.10</td>
<td>0.92/0.89</td>
<td>0.52, 1.52</td>
<td>0.20/0.18</td>
<td>0.02, 0.51</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ U~(0,3)</td>
<td>16.4</td>
<td>128.9 (13.0)</td>
<td>50.3</td>
<td>0.89/0.89</td>
<td>0.72, 1.10</td>
<td>0.92/0.89</td>
<td>0.52, 1.52</td>
<td>0.20/0.18</td>
<td>0.02, 0.51</td>
</tr>
<tr>
<td/>
<td/>
<td>HN on τ, variance = 1</td>
<td>16.4</td>
<td>126.2 (12.9)</td>
<td>51.7</td>
<td>0.89/0.89</td>
<td>0.72, 1.10</td>
<td>0.92/0.89</td>
<td>0.53, 1.49</td>
<td>0.19/0.18</td>
<td>0.02, 0.48</td>
</tr>
<tr>
<td/>
<td/>
<td>HN on τ, variance = 100</td>
<td>16.4</td>
<td>127.5 (13.0)</td>
<td>52.1</td>
<td>0.89/0.89</td>
<td>0.72, 1.10</td>
<td>0.92/0.89</td>
<td>0.52, 1.52</td>
<td>0.20/0.18</td>
<td>0.02, 0.50</td>
</tr>
<tr>
<td/>
<td/>
<td>HN on τ<sup>2</sup>
</td>
<td>15.6</td>
<td>128.5 (13.3)</td>
<td>58.4</td>
<td>0.90/0.89</td>
<td>0.71, 1.11</td>
<td>0.93/0.89</td>
<td>0.50, 1.59</td>
<td>0.23/0.22</td>
<td>0.07, 0.47</td>
</tr>
<tr>
<td/>
<td/>
<td>Inverse gamma</td>
<td>17.0</td>
<td>128.2 (12.8)</td>
<td>65.9</td>
<td>0.89/0.88</td>
<td>0.74, 1.06</td>
<td>0.90/0.88</td>
<td>0.59, 1.35</td>
<td>0.15/0.13</td>
<td>0.03, 0.39</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ<sup>2</sup> U~(0,3)</td>
<td>15.5</td>
<td>128.8 (13.7)</td>
<td>73.2</td>
<td>0.90/0.89</td>
<td>0.68, 1.15</td>
<td>0.95/0.89</td>
<td>0.44, 1.80</td>
<td>0.28/0.25</td>
<td>0.07, 0.68</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ<sup>2</sup> U~(0,9)</td>
<td>15.6</td>
<td>124.7 (13.7)</td>
<td>74.3</td>
<td>0.90/0.89</td>
<td>0.68, 1.16</td>
<td>0.95/0.89</td>
<td>0.43, 1.82</td>
<td>0.28/0.25</td>
<td>0.07, 0.69</td>
</tr>
<tr>
<td colspan="9"><hr/></td>
</tr>
<tr>
<td colspan="12">Moderate outcomes</td>
</tr>
<tr>
<td> Falls (n = 13)</td>
<td align="center" rowspan="2">23%<break/>0.10</td>
<td>DuMouchel on τ</td>
<td>28.5</td>
<td>197.0 (15.7)</td>
<td>38.7</td>
<td>0.90/0.90</td>
<td>0.80, 0.99</td>
<td>0.90/0.90</td>
<td>0.72, 1.07</td>
<td>0.06/0.05</td>
<td>0.00, 0.21</td>
</tr>
<tr>
<td/>
<td>Uniform shrinkage on τ<sup>2</sup>
</td>
<td>27.9</td>
<td>197.4 (16.7)</td>
<td>43.4</td>
<td>0.89/0.89</td>
<td>0.78, 0.99</td>
<td>0.89/0.89</td>
<td>0.67, 1.13</td>
<td>0.09/0.08</td>
<td>0.02, 0.23</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ U~(0,3)</td>
<td>27.9</td>
<td>197.5 (16.8)</td>
<td>43.6</td>
<td>0.89/0.89</td>
<td>0.77, 0.99</td>
<td>0.89/0.90</td>
<td>0.64, 1.15</td>
<td>0.10/0.08</td>
<td>0.00, 0.30</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ U~(0,<inline-formula id="inline-formula14-0272989X12453504">
<mml:math display="inline" id="math19-0272989X12453504">
<mml:mrow>
<mml:msqrt>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
</mml:msqrt>
</mml:mrow>
</mml:math>
</inline-formula>)</td>
<td>27.9</td>
<td>193.4 (16.9)</td>
<td>43.6</td>
<td>0.89/0.89</td>
<td>0.77, 0.99</td>
<td>0.89/0.90</td>
<td>0.64, 1.16</td>
<td>0.10/0.08</td>
<td>0.00, 0.31</td>
</tr>
<tr>
<td/>
<td/>
<td>HN on τ, variance = 100</td>
<td>27.9</td>
<td>196.2 (16.8)</td>
<td>43.9</td>
<td>0.89/0.89</td>
<td>0.77, 0.99</td>
<td>0.89/0.89</td>
<td>0.64, 1.15</td>
<td>0.10/0.08</td>
<td>0.00, 0.30</td>
</tr>
<tr>
<td/>
<td/>
<td>HN on τ, variance = 1</td>
<td>28.0</td>
<td>194.7 (16.8)</td>
<td>46.4</td>
<td>0.89/0.89</td>
<td>0.77, 0.99</td>
<td>0.89/0.89</td>
<td>0.64, 1.15</td>
<td>0.10/0.08</td>
<td>0.00, 0.30</td>
</tr>
<tr>
<td/>
<td/>
<td>HN on τ<sup>2</sup>
</td>
<td>27.1</td>
<td>198.2 (18.4)</td>
<td>54.3</td>
<td>0.87/0.88</td>
<td>0.73, 0.99)</td>
<td>0.89/0.88</td>
<td>0.57, 1.27</td>
<td>0.15/0.14</td>
<td>0.03, 0.37</td>
</tr>
<tr>
<td/>
<td/>
<td>Inverse gamma</td>
<td>28.1</td>
<td>201.1 (23.5)</td>
<td>54.5</td>
<td>0.89/0.89</td>
<td>0.79, 0.99</td>
<td>0.90/0.90</td>
<td>0.69, 1.11</td>
<td>0.08/0.07</td>
<td>0.02, 0.24</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ<sup>2</sup> U~(0,3)</td>
<td>27.0</td>
<td>198.5 (18.8)</td>
<td>59.3</td>
<td>0.87/0.87</td>
<td>0.72, 1.00</td>
<td>0.89/0.88</td>
<td>0.54, 1.30</td>
<td>0.16/0.14</td>
<td>0.03, 0.42</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ<sup>2</sup> U~(0,9)</td>
<td>27.0</td>
<td>194.3 (18.7)</td>
<td>66.9</td>
<td>0.87/0.88</td>
<td>0.72, 1.00</td>
<td>0.89/0.89</td>
<td>0.54, 1.30</td>
<td>0.16/0.14</td>
<td>0.03, 0.42</td>
</tr>
<tr>
<td colspan="9"><hr/></td>
</tr>
<tr>
<td rowspan="2"> Sore throat symptom day 6–8 (n = 13)</td>
<td align="center" rowspan="2">71%<break/>0.67</td>
<td>HN on τ<sup>2</sup>
</td>
<td>27.8</td>
<td>135.7 (18.7)</td>
<td>154.1</td>
<td>0.34/0.33</td>
<td>0.17, 0.57</td>
<td>0.47/0.33</td>
<td>0.06, 1.75</td>
<td>0.79/0.79</td>
<td>0.49, 1.11</td>
</tr>
<tr>
<td>Uniform shrinkage on τ<sup>2</sup>
</td>
<td>27.4</td>
<td>135.9 (19.5)</td>
<td>163.9</td>
<td>0.33/0.32</td>
<td>0.14, 0.58</td>
<td>0.56/0.32</td>
<td>0.03, 2.32</td>
<td>0.93/0.88</td>
<td>0.47, 1.69</td>
</tr>
<tr>
<td/>
<td/>
<td>DuMouchel on τ</td>
<td>26.9</td>
<td>135.6 (19.7)</td>
<td>172.2</td>
<td>0.32/0.31</td>
<td>0.12, 0.59</td>
<td>0.69/0.31</td>
<td>0.03, 2.75</td>
<td>1.03/0.97</td>
<td>0.50, 1.93</td>
</tr>
<tr>
<td/>
<td/>
<td>HN on τ, variance = 1</td>
<td>26.7</td>
<td>132.6 (19.6)</td>
<td>177.6</td>
<td>0.32/0.30</td>
<td>0.13, 0.59</td>
<td>0.63/0.30</td>
<td>0.03, 2.75</td>
<td>1.04/1.00</td>
<td>0.54, 1.79</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ U~(0,<inline-formula id="inline-formula15-0272989X12453504">
<mml:math display="inline" id="math20-0272989X12453504">
<mml:mrow>
<mml:msqrt>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
</mml:msqrt>
</mml:mrow>
</mml:math>
</inline-formula>)</td>
<td>26.4</td>
<td>131.1 (19.7)</td>
<td>181.1</td>
<td>0.31/0.29</td>
<td>0.12, 0.59</td>
<td>0.61/0.30</td>
<td>0.02, 2.97</td>
<td>1.10/1.09</td>
<td>0.58, 1.67</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ<sup>2</sup> U~(0,3)</td>
<td>26.1</td>
<td>135.0 (19.8)</td>
<td>192.7</td>
<td>0.30/0.29</td>
<td>0.11, 0.60</td>
<td>0.66/0.29</td>
<td>0.02, 3.53</td>
<td>1.18/1.18</td>
<td>0.64, 1.69</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ U~(0,3)</td>
<td>26.2</td>
<td>135.3 (20.1)</td>
<td>193.7</td>
<td>0.30/0.29</td>
<td>0.10, 0.61</td>
<td>0.95/0.29</td>
<td>0.01, 3.94</td>
<td>1.22/1.14</td>
<td>0.59, 2.33</td>
</tr>
<tr>
<td/>
<td/>
<td>HN on τ, variance = 100</td>
<td>26.2</td>
<td>134.0 (20.1)</td>
<td>196.3</td>
<td>0.30/0.29</td>
<td>0.10, 0.61</td>
<td>4.01/0.29</td>
<td>0.01, 4.09</td>
<td>1.24/1.14</td>
<td>0.58, 1.44</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ<sup>2</sup> U~(0,9)</td>
<td>25.8</td>
<td>130.9 (20.3)</td>
<td>206.9</td>
<td>0.29/0.27</td>
<td>0.08, 0.63</td>
<td>1.24/0.27</td>
<td>0.00, 5.44</td>
<td>1.38/1.29</td>
<td>0.66, 2.59</td>
</tr>
<tr>
<td/>
<td/>
<td>Inverse gamma</td>
<td>26.7</td>
<td>135.2 (19.7)</td>
<td>482.3</td>
<td>0.31/0.30</td>
<td>0.11, 0.59</td>
<td>2.13/0.30</td>
<td>0.02, 3.10</td>
<td>1.09/1.02</td>
<td>0.52, 2.09</td>
</tr>
<tr>
<td colspan="9"><hr/></td>
</tr>
<tr>
<td colspan="12">Frequent outcomes</td>
</tr>
<tr>
<td> Hot flushes (n = 5)</td>
<td align="center" rowspan="2">34%<break/>0.50</td>
<td>HN on τ<sup>2</sup>
</td>
<td>10.1</td>
<td>54.4 (7.4)</td>
<td>23.3</td>
<td>0.12/0.11</td>
<td>0.04, 0.26</td>
<td>0.16/0.11</td>
<td>0.02, 0.59</td>
<td>0.64/0.63</td>
<td>0.14, 1.21</td>
</tr>
<tr>
<td/>
<td>Uniform shrinkage on τ<sup>2</sup>
</td>
<td>10.4</td>
<td>54.5 (7.2)</td>
<td>24.9</td>
<td>0.12/0.11</td>
<td>0.05, 0.25</td>
<td>8.42/0.11</td>
<td>0.02, 0.55</td>
<td>0.56/0.49</td>
<td>0.09, 1.47</td>
</tr>
<tr>
<td/>
<td/>
<td>DuMouchel on τ</td>
<td>10.8</td>
<td>54.6 (6.8)</td>
<td>26.6</td>
<td>0.12/0.11</td>
<td>0.05, 0.24</td>
<td align="center">&gt;100/0.11</td>
<td>0.03, 0.46</td>
<td>0.42/0.30</td>
<td>0.01, 1.52</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ U~(0,<inline-formula id="inline-formula16-0272989X12453504">
<mml:math display="inline" id="math21-0272989X12453504">
<mml:mrow>
<mml:msqrt>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
</mml:msqrt>
</mml:mrow>
</mml:math>
</inline-formula>)</td>
<td>10.3</td>
<td>50.5 (7.4)</td>
<td>27.9</td>
<td>0.12/0.11</td>
<td>0.04, 0.27</td>
<td>0.18/0.11</td>
<td>0.02, 0.74</td>
<td>0.64/0.57</td>
<td>0.03, 1.59</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ U~(0,3)</td>
<td>10.2</td>
<td>54.8 (7.6)</td>
<td>30.3</td>
<td>0.13/0.11</td>
<td>0.04, 0.33</td>
<td>0.43/0.11</td>
<td>0.01, 1.19</td>
<td>0.78/0.64</td>
<td>0.04, 2.35</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ<sup>2</sup> U~(0,3)</td>
<td>9.8</td>
<td>54.7 (8.0)</td>
<td>31.5</td>
<td>0.13/0.11</td>
<td>0.03, 0.33</td>
<td>0.24/0.11</td>
<td>0.01, 1.22</td>
<td>0.93/0.92</td>
<td>0.19, 1.67</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ<sup>2</sup> U~(0,9)</td>
<td>9.8</td>
<td>50.8 (8.3)</td>
<td>47.1</td>
<td>0.14/0.11</td>
<td>0.03, 0.47</td>
<td>1.18/0.11</td>
<td>0.00, 3.18</td>
<td>1.23/1.11</td>
<td>0.22, 2.75</td>
</tr>
<tr>
<td/>
<td/>
<td>HN on τ, variance = 1</td>
<td>10.5</td>
<td>51.8 (7.2)</td>
<td>47.5</td>
<td>0.12/0.11</td>
<td>0.04, 0.26</td>
<td>0.18/0.11</td>
<td>0.02, 0.59</td>
<td>0.55/0.47</td>
<td>0.02, 1.53</td>
</tr>
<tr>
<td/>
<td/>
<td>Inverse gamma</td>
<td>11.0</td>
<td>55.5 (8.3)</td>
<td>51.1</td>
<td>0.12/0.11</td>
<td>0.04, 0.23</td>
<td align="center">&gt;100/0.11</td>
<td>0.03, 0.43</td>
<td>0.38/0.22</td>
<td>0.03, 1.53</td>
</tr>
<tr>
<td/>
<td/>
<td>HN on τ, variance = 100</td>
<td>10.2</td>
<td>54.5 (7.4)</td>
<td>140.6</td>
<td>0.14/0.11</td>
<td>0.04, 0.36</td>
<td align="center">&gt;100/0.11</td>
<td>0.01, 1.56</td>
<td>0.84/0.65</td>
<td>0.03, 2.84</td>
</tr>
<tr>
<td colspan="9"><hr/></td>
</tr>
<tr>
<td rowspan="2"> Sore throat symptom day 3 (n = 12)</td>
<td align="center" rowspan="2">74%<break/>0.73</td>
<td>HN on τ<sup>2</sup>
</td>
<td>25.7</td>
<td>157.3 (20.7)</td>
<td>342.8</td>
<td>0.34/0.34</td>
<td>0.21, 0.53</td>
<td>0.45/0.34</td>
<td>0.07, 1.51</td>
<td>0.71/0.70</td>
<td>0.48, 0.96</td>
</tr>
<tr>
<td>Uniform shrinkage on τ<sup>2</sup>
</td>
<td>25.4</td>
<td>160.4 (21.1)</td>
<td>363.6</td>
<td>0.35/0.34</td>
<td>0.20, 0.56</td>
<td>0.50/0.33</td>
<td>0.06, 1.85</td>
<td>0.79/0.76</td>
<td>0.46, 1.30</td>
</tr>
<tr>
<td/>
<td/>
<td>DuMouchel on τ</td>
<td>25.1</td>
<td>160.3 (21.2)</td>
<td>379.3</td>
<td>0.35/0.33</td>
<td>0.19, 0.58</td>
<td>0.53/0.33</td>
<td>0.05, 2.13</td>
<td>0.85/0.82</td>
<td>0.49, 1.42</td>
</tr>
<tr>
<td/>
<td/>
<td>HN on τ, variance = 1</td>
<td>24.8</td>
<td>157.3 (21.4)</td>
<td>388.2</td>
<td>0.35/0.33</td>
<td>0.18, 0.59</td>
<td>0.55/0.33</td>
<td>0.05, 2.27</td>
<td>0.89/0.85</td>
<td>0.52, 1.44</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ (U~0,<inline-formula id="inline-formula17-0272989X12453504">
<mml:math display="inline" id="math22-0272989X12453504">
<mml:mrow>
<mml:msqrt>
<mml:mrow>
<mml:mn>3</mml:mn>
</mml:mrow>
</mml:msqrt>
</mml:mrow>
</mml:math>
</inline-formula>)</td>
<td>24.6</td>
<td>155.7 (21.6)</td>
<td>349.7</td>
<td>0.35/0.33</td>
<td>0.18, 0.60</td>
<td>0.58/0.33</td>
<td>0.04, 2.54</td>
<td>0.94/0.90</td>
<td>0.54, 1.53</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ (U~0,3)</td>
<td>24.6</td>
<td>159.9 (21.4)</td>
<td>405.9</td>
<td>0.35/0.33</td>
<td>0.18, 0.61</td>
<td>0.62/0.33</td>
<td>0.04, 2.69</td>
<td>0.96/0.91</td>
<td>0.54, 1.65</td>
</tr>
<tr>
<td/>
<td/>
<td>HN on τ, variance = 100</td>
<td>24.6</td>
<td>157.1 (21.5)</td>
<td>412.8</td>
<td>0.35/0.33</td>
<td>0.18, 0.61</td>
<td>0.66/0.33</td>
<td>0.04, 2.69</td>
<td>0.96/0.91</td>
<td>0.54, 1.66</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ<sup>2</sup> (U~0,3)</td>
<td>24.4</td>
<td>159.7 (21.5)</td>
<td>418.4</td>
<td>0.35/0.33</td>
<td>0.17, 0.62</td>
<td>0.63/0.33</td>
<td>0.04, 2.94</td>
<td>1.01/0.97</td>
<td>0.58, 1.59</td>
</tr>
<tr>
<td/>
<td/>
<td>Uniform on τ<sup>2</sup> (U~0,9)</td>
<td>24.3</td>
<td>155.6 (21.6)</td>
<td>424.8</td>
<td>0.35/0.33</td>
<td>0.17, 0.64</td>
<td>0.76/0.33</td>
<td>0.03, 3.25</td>
<td>1.04/0.99</td>
<td>0.58, 1.84</td>
</tr>
<tr>
<td/>
<td/>
<td>Inverse gamma</td>
<td>24.9</td>
<td>160.1 (21.3)</td>
<td>621.9</td>
<td>0.35/0.33</td>
<td>0.18, 0.59</td>
<td>0.56/0.33</td>
<td>0.05, 2.28</td>
<td>0.88/0.84</td>
<td>0.50, 1.50</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0272989X12453504">
<p>Note: The gray-shaded cells refer to the 3 best priors chosen by RD, DIC, or PD. τ<sup>2</sup> = between-study variance; τ or SD = between-study standard deviation; RD = total residual deviance; DIC = deviance information criterion (total DICs include constant values for τ<sup>2</sup> and τ as calculated in WinBUGS); pD = the effective number of parameters; PD = total predictive deviance; N = number of trials, I<sup>2</sup> = I<sup>2</sup> statistics; ; OR = odds ratio; CrI = credible interval; HN = the half-normal distribution.</p>
</fn>
<fn id="table-fn6-0272989X12453504">
<label>a.</label>
<p>Between-study standard deviations (SD) were calculated by the method of moments.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section5-0272989X12453504">
<title>Predictive deviance</title>
<p>No model was consistently best fitting when we assessed model fit using the total PD. For rare outcomes, models based on the half-normal prior on τ (variance = 1) and the DuMouchel prior were the best fitting. In contrast, for moderate and frequent outcomes, models based on the half-normal prior on τ<sup>2</sup> and the shrinkage priors (DuMouchel and uniform shrinkage) were optimal (<xref ref-type="table" rid="table3-0272989X12453504">Table 3</xref>). The models with the worst fit were based on inverse gamma, uniform on τ<sup>2</sup>, and half-normal on τ (variance = 100). We observed a wide range of values of PD between the best- and the worst-fitting models (23–622). As expected, the difference between the best- and the worst-fitting models increased as between-study heterogeneity increased (as measured by the I<sup><xref ref-type="bibr" rid="bibr2-0272989X12453504">2</xref></sup> statistic), particularly for moderate and frequent outcomes (<xref ref-type="table" rid="table3-0272989X12453504">Table 3</xref>). The rank order of the priors did not change after excluding outlying trials (Appendix 3). In addition, differences between the estimates of PD for the 3 best priors were less than 5 in almost all homogeneous meta-analyses (i.e., acute rheumatic fever [I<sup>2</sup> = 21%], falls [I<sup>2</sup> = 25%], and hot flushes [I<sup>2</sup> = 34%]; <xref ref-type="table" rid="table3-0272989X12453504">Table 3</xref>).</p>
</sec>
</sec>
<sec id="section6-0272989X12453504">
<title>Prior on τ<sup>2</sup> and Treatment Effects in Current and Future Studies</title>
<p>The posterior distributions for the population odds ratio (OR) were relatively stable across the 10 priors (<xref ref-type="table" rid="table3-0272989X12453504">Table 3</xref>). The posterior means were similar for the best- and the worst-fitting prior (as determined by RD); however, the 95% CrIs were somewhat narrower for the worst-fitting priors.</p>
<p>The choice of prior strongly influenced the posterior predictive distributions of treatment effects in future studies (<xref ref-type="table" rid="table3-0272989X12453504">Table 3</xref>; <xref ref-type="fig" rid="fig2-0272989X12453504">Figure 2</xref>). The posterior predictive distribution corresponding to the prior giving the best RD was also frequently different from the posterior distribution corresponding to the prior giving the best PD. For example, in the analysis of 6 studies of the effect of vitamin D on hip fractures, an analysis of the prior with the lowest RD (uniform on τ<sup>2</sup>) resulted in a predicted OR of 2.3 but with a very wide 95% CrI ranging from 0.1 to 5.6, suggesting implausibly large risk reductions but also high risks of harm. In contrast, an analysis with the prior with the lowest PD (DuMouchel on τ) resulted in a predicted OR of 0.8 with 95% CrI from 0.4 to 1.3 (<xref ref-type="table" rid="table3-0272989X12453504">Table 3</xref>; <xref ref-type="fig" rid="fig2-0272989X12453504">Figure 2</xref>). Similar results were seen comparing RD and PD for meta-analyses analyzing sore throat symptoms, acute rheumatic fever, and hot flushes. We also observed different posterior means of future study ORs using the best and the worst priors by PD. In the example of sore throat symptoms at day 6 to 8, the future study OR given by the best prior (half-normal on τ<sup>2</sup>) was more sensible (0.5, 95% CrI: 0.1, 1.8) than the one given by the worst prior (inverse gamma; 2.1, 95% CrI: 0.0, 3.1; <xref ref-type="fig" rid="fig2-0272989X12453504">Figure 2</xref>).</p>
<fig id="fig2-0272989X12453504" position="float">
<label>Figure 2</label>
<caption>
<p>Future study odds ratios (future OR) as per the best and the worst priors on the between-study heterogeneity parameter according to residual deviance (RD) and total predictive deviance (PD): examples for rare (acute rheumatic fever [ARF]), moderate (symptoms of sore throat at day 6-8), and frequent outcomes (hot flushes and sore throat at day 3).</p>
</caption>
<graphic xlink:href="10.1177_0272989X12453504-fig2.tif"/>
</fig>
</sec>
<sec id="section7-0272989X12453504">
<title>Effect of the Priors on τ<sup>2</sup> on the Estimation of Between-Study Heterogeneity</title>
<p>The posterior distributions for the between-study standard deviation were different for priors determined by RD and PD (<xref ref-type="table" rid="table3-0272989X12453504">Table 3</xref>). In most examples, the posterior means for the between-study standard deviation given by the priors with the worst RD were closest to the corresponding estimates calculated by the method of moments. A uniform on τ<sup>2</sup> was always the best prior by RD, but it was never the best prior for predictions and was even the worst prior by PD in several examples (i.e., hip fractures, 8 trials; acute rheumatic fever, and falls). Compared with priors with the best PD, priors with the best RD generated a larger between-study variance (<xref ref-type="table" rid="table3-0272989X12453504">Table 3</xref>).</p>
</sec>
</sec>
<sec id="section8-0272989X12453504" sec-type="discussion">
<title>Discussion</title>
<p>We assessed the goodness of fit of 10 previously proposed<sup><xref ref-type="bibr" rid="bibr14-0272989X12453504">14</xref>,<xref ref-type="bibr" rid="bibr15-0272989X12453504">15</xref>,<xref ref-type="bibr" rid="bibr26-0272989X12453504">26</xref></sup> prior distributions on τ<sup>2</sup> in Bayesian random-effects meta-analyses of binary outcomes. The 3 goodness-of-fit measures used to assess model fit identified different priors as optimal. However, we found substantial differences in model fit across the 10 candidate priors only when we used predictive deviance as the goodness-of-fit criterion.</p>
<p>Our findings that RD and DIC give preference to uniform distributions on τ or τ<sup>2</sup> are in partial agreement with the conclusions of the simulation study by Gelman that identified uniform on τ<sup>2</sup> as best for big sample sizes and the half-<italic>t</italic> priors as best for small sample sizes.<sup><xref ref-type="bibr" rid="bibr15-0272989X12453504">15</xref></sup> As in Gelman, we also found that models based on inverse gamma performed poorly.<sup><xref ref-type="bibr" rid="bibr15-0272989X12453504">15</xref></sup></p>
<p>Total PD was computed by cross-validation<sup><xref ref-type="bibr" rid="bibr32-0272989X12453504">32</xref></sup> and was used to examine the internal validity of the meta-analysis models for predicting treatment effects in future studies. To our knowledge, this leave-one-out cross-validation measure of goodness of fit has not been reported in hierarchical random-effects meta-analysis. However, cross-validation has been suggested for calculation of predictive posterior <italic>P</italic> values to assess outliers in Bayesian hierarchical models.<sup><xref ref-type="bibr" rid="bibr34-0272989X12453504">34</xref></sup> Ades and Cliffe<sup><xref ref-type="bibr" rid="bibr27-0272989X12453504">27</xref></sup> applied this method to examine the influence of outlying studies used to estimate the parameters of decision-analytic models. During cross-validations, they omitted the outlier studies, generated their replicates from the predictive distributions (based on full data), and obtained predictive Bayesian <italic>P</italic> values (that compared observed to replicate data points). This approach is useful for identification of outlying individual studies but does not give a global measure of the predictive accuracy across any future study.</p>
<p>PD identified half-normal on τ<sup>2</sup> and the shrinkage priors as best. Although these priors are assumed to be vague priors, they are more informative than a uniform prior on τ<sup>2</sup>. The half-normal prior distribution on τ<sup>2</sup> provides adequate coverage of between-study heterogeneity by including τ values from 0 to 3, corresponding to a range in variability from nil to very large; however, it also specifies very small probabilities for these extreme values of τ (<xref ref-type="fig" rid="fig1-0272989X12453504">Figure 1</xref>). In contrast, a uniform on τ<sup>2</sup> with a large range (e.g., 0 to 9) may not be sensible; with a relatively small number of trials, the posterior puts probability on unrealistically large values for τ<sup>2</sup>, values that indicate independence of the pooled trials.<sup><xref ref-type="bibr" rid="bibr26-0272989X12453504">26</xref></sup> Spieghalter and others<sup><xref ref-type="bibr" rid="bibr26-0272989X12453504">26</xref></sup> recommend use of the half-normal priors on τ in situations in which prior information is important. This could apply to those cases in which current evidence should not dominate previous knowledge but should be incorporated into it to be transformed into a coherent whole. The other best priors by PD, the shrinkage priors (uniform shrinkage on τ<sup>2</sup> and DuMouchel on τ), can be somewhat more informative than the half-normal priors as they incorporate available information on within-study variation to estimate the parameters of the prior distribution (<xref ref-type="table" rid="table2-0272989X12453504">Table 2</xref>; see the calculations of <inline-formula id="inline-formula18-0272989X12453504"><mml:math display="inline" id="math23-0272989X12453504"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>).<sup><xref ref-type="bibr" rid="bibr26-0272989X12453504">26</xref></sup> More specifically, a large value of <inline-formula id="inline-formula19-0272989X12453504"><mml:math display="inline" id="math24-0272989X12453504"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> or large average within-study variance results in less shrinkage or a wider prior distribution on between-study variance. Thus, less well-estimated individual treatment effects lead to a prior allowing more inconsistency in the evidence. In contrast, a small value of <inline-formula id="inline-formula20-0272989X12453504"><mml:math display="inline" id="math25-0272989X12453504"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> results in more shrinkage and a narrower distribution on the between-study variance; well-estimated individual effects lead to a prior allowing more consistency in the evidence. Daniels<sup><xref ref-type="bibr" rid="bibr37-0272989X12453504">37</xref></sup> investigated the properties of uniform shrinkage on τ<sup>2</sup> and the DuMouchel prior and found that they produced better estimates of τ<sup>2</sup> (compared with uniform [flat] prior, which pulled the estimate away from zero). More importantly, the shrinkage priors were able to detect the situation of no heterogeneity.<sup><xref ref-type="bibr" rid="bibr37-0272989X12453504">37</xref></sup> Daniels recommended the shrinkage priors in very small samples. A simulation study by Lambert and others,<sup><xref ref-type="bibr" rid="bibr14-0272989X12453504">14</xref></sup> which evaluated the influence of vague priors on the posteriors of population OR and between-study standard deviation, indicated that the DuMouchel prior caused computational problems with convergence and slow mixing of Markov chain Monte Carlo (MCMC) chains in meta-analyses with a large number of 30 studies and a small between-study standard deviation. However, there is little research on the effect of the shrinkage priors on the predictions of future treatment effects in Bayesian meta-analyses.</p>
<p>Our study showed wide variations in the posteriors of the predicted treatment effects depending on the choice of goodness-of-fit measure (RD v. PD) and degree of between-study heterogeneity. We consistently found that the predictions of the future treatment effect were more sensible if we specified the priors with the lowest PD, not with the lowest RD. The clinical importance of assessing model fit was particularly pronounced in the examples of hot flushes and acute rheumatic fever. In the case of hot flushes with a small number of homogeneous studies, we found a switch in predictive distribution from a highly convincing risk reduction when the prior with the best PD was used (OR = 0.16, 95% CrI: 0.02, 0.59), to an inconclusive one (OR = 0.24, 95% CrI: 0.01–1.22) when the prior with the best RD was used (<xref ref-type="fig" rid="fig2-0272989X12453504">Figure 2</xref>). The prior with the best PD gives a prediction interval entirely below 1, indicating that hormone replacement therapy is beneficial for treatment of hot flushes when applied in at least 95% of the individual trial settings and suggesting no need for further research in this area.</p>
<p>As expected, we found that a uniform on τ<sup>2</sup> (the optimal prior by RD) gave larger estimates of between-study variance compared with the optimal priors chosen by PD. Also, we found that the posterior means and medians for the τ parameter given by the priors with the worst RD were closest to the standard deviations calculated by the method of moments. This confirms difficulties in quantifying the true between-study variance by the method of moments that treats between-study variance as fixed and known.<sup><xref ref-type="bibr" rid="bibr3-0272989X12453504">3</xref>,<xref ref-type="bibr" rid="bibr19-0272989X12453504">19</xref></sup> This assumption is equivalent to having a totally informative prior distribution on the value of τ<sup>2</sup>.<sup><xref ref-type="bibr" rid="bibr38-0272989X12453504">38</xref></sup> Our finding also indicates the importance of assessing the goodness of fit of models with different priors on between-study variance, as some may lead to better estimation than others of the τ parameter. Furthermore, our results suggest that the disease frequency is associated with some additional variability. For example, in studies with rare outcomes, there was still a great deal of uncertainty about the value of τ<sup>2</sup> even with the best-fitting priors on τ<sup>2</sup>, producing the inconclusive estimates of future ORs. Lambert and others<sup><xref ref-type="bibr" rid="bibr14-0272989X12453504">14</xref></sup> also showed that in models with sparse data or with a small number of units that contribute to the estimation of between-study variance, vague prior distributions overwhelmed the data, resulting in meaningless inferences. Finally, other sources of variation in random-effects meta-analysis caused by systematic or other type of bias require special attention<sup><xref ref-type="bibr" rid="bibr3-0272989X12453504">3</xref></sup> and need to be investigated separately from the priors on between-study variance.</p>
<p>Some methods of classical meta-analysis such as cumulative meta-analysis summarize the treatment effects of different trials in a sequence up to some point in time, but they do not make any prediction of future treatment effects.<sup><xref ref-type="bibr" rid="bibr2-0272989X12453504">2</xref></sup> A valuable feature of Bayesian random-effects meta-analysis is to generate a genuine predictive distribution of the treatment effect for a future study through MCMC simulations.<sup><xref ref-type="bibr" rid="bibr3-0272989X12453504">3</xref></sup> Riley and others<sup><xref ref-type="bibr" rid="bibr5-0272989X12453504">5</xref></sup> and Higgins and others<sup><xref ref-type="bibr" rid="bibr3-0272989X12453504">3</xref></sup> indicate that estimation of prediction intervals provides better insight of uncertainty around the true treatment effect as it accounts for the uncertainty around the pooled estimate, the estimate of τ, and the uncertainty around τ. Proper incorporation of explained and unexplained between-study heterogeneity around the treatment effect is important for decision modeling and economic evaluations. As a result, Spiegelhalter and others<sup><xref ref-type="bibr" rid="bibr1-0272989X12453504">1</xref></sup> and Ades and others<sup><xref ref-type="bibr" rid="bibr6-0272989X12453504">6</xref></sup> propose the use of the predictive distribution of the future treatment effect instead of the random-effects mean to ensure inclusion of all variation around the true treatment effect, which is not fully captured in the posterior distribution of the population treatment effect. Therefore, information about the uncertainty of a future treatment effect reflected by prediction intervals or predictive distributions is important for clinicians, clinician scientists who undertake trials, and decision analysts.</p>
<p>Our study extends the previous research on priors on between-study heterogeneity and shows that it is worth investigating a range of vague priors on τ<sup>2</sup> when predictions are an important component of the Bayesian meta-analysis. Assessment of the effect of priors on between-study variance should be particularly important to perform in studies that use complex Bayesian methods (e.g., network meta-analysis) that incorporate indirect treatment comparisons.<sup><xref ref-type="bibr" rid="bibr17-0272989X12453504">17</xref>,<xref ref-type="bibr" rid="bibr33-0272989X12453504">33</xref></sup> Because calculation of PD by cross-validations has not been used in meta-analyses, it deserves further research and application. Future research should also evaluate whether the techniques for assessing outliers in networks (e.g., cross-validation and node-splitting) are also influenced by noninformative priors and whether the use of informative priors or empirical Bayes methods<sup><xref ref-type="bibr" rid="bibr39-0272989X12453504">39</xref></sup> can prevent these methods from underdetecting outliers.</p>
<p>In addition, our study suggests that substantial variability around the prediction, even in the presence of the best-fitting prior on τ<sup>2</sup>, can be a sign of a gap in knowledge and an indication for future research. In such a case, the prediction interval can be pragmatically used to estimate a sample size of a future study.<sup><xref ref-type="bibr" rid="bibr9-0272989X12453504">9</xref><xref ref-type="bibr" rid="bibr10-0272989X12453504"/>–<xref ref-type="bibr" rid="bibr11-0272989X12453504">11</xref>,<xref ref-type="bibr" rid="bibr40-0272989X12453504">40</xref></sup> In small studies and studies with rare outcomes, the number of units contributing to the estimation of the between-study variation is small, and a meaningless prediction can also indicate an inappropriate use of vague priors. Therefore, in accordance with the arguments in Lambert and others,<sup><xref ref-type="bibr" rid="bibr14-0272989X12453504">14</xref></sup> we also caution that the role of informative priors on τ<sup>2</sup> should certainly be explored in the analyses of rare outcomes or the analyses including small number of trials. In these cases, informative priors on between-study variance serve to limit unreasonably large between-study variability. For instance, we could use a prior that gives no weight for values of τ greater than 0.5 because this limit is considered substantial heterogeneity,<sup><xref ref-type="bibr" rid="bibr26-0272989X12453504">26</xref></sup> or we could empirically determine informative priors based on previous evidence, as was done by Pullenayegum.<sup><xref ref-type="bibr" rid="bibr16-0272989X12453504">16</xref></sup></p>
<p>Our study has some limitations. First, we included a relatively small number of meta-analyses and restricted our sample to those that assessed binary outcomes. It is possible that by chance, the half-normal or shrinkage priors on between-study heterogeneity fit best here and that the findings are not generalizable. Second, one could argue that choosing the best prior on between-study variance via a measure of model fit is at odds with the very notion of choosing a prior. However, we are choosing between ostensibly noninformative priors, all of which express relative prior ignorance of the value of the heterogeneity parameter. Also, although an analyst is in charge of choosing priors in Bayesian models, it is recommended that sensitivity analyses be performed to evaluate the influence of the specified priors on study conclusions.<sup><xref ref-type="bibr" rid="bibr15-0272989X12453504">15</xref>,<xref ref-type="bibr" rid="bibr28-0272989X12453504">28</xref>,<xref ref-type="bibr" rid="bibr29-0272989X12453504">29</xref></sup> For example, Pullenayegum<sup><xref ref-type="bibr" rid="bibr16-0272989X12453504">16</xref></sup> used DIC to evaluate model fit of the empirically estimated (informative) priors on between-study variance. Accordingly, our research furthers the current knowledge and improves the tools for performing sensitivity analyses on priors for between-study variance by suggesting different goodness-of-fit criteria. Third, we decided to research the priors on between-study variance that have been suggested by the Bayesian community.<sup><xref ref-type="bibr" rid="bibr14-0272989X12453504">14</xref>,<xref ref-type="bibr" rid="bibr15-0272989X12453504">15</xref>,<xref ref-type="bibr" rid="bibr26-0272989X12453504">26</xref></sup> Having a palette of different noninformative priors supports an idea that even ignorance about the amount of between-study heterogeneity can be described in many ways. These priors can be parameterized by the standard deviation, precision, or variance, putting different weights on different parts of the parameter. In case of large amounts of data, which in this setting would be large numbers of studies, the data should overwhelm the prior and the posterior will depend only weakly on the prior; thus, noninformative and carefully obtained priors should produce similar posteriors.<sup><xref ref-type="bibr" rid="bibr41-0272989X12453504">41</xref></sup> Nevertheless, we showed that in random-effects meta-analyses of a typical size, the prior on τ<sup>2</sup> is likely to influence predictions if assumed uncertainty on between-study variance is large and not estimated well. Last, we did not analyze simulated data, but we did perform cross-validations. We chose an empirical design to estimate real prediction intervals from the observed clinical trial data that may not be possible to obtain by a simulation study with “well-behaved” data.<sup><xref ref-type="bibr" rid="bibr38-0272989X12453504">38</xref></sup> However, larger empirical studies need to establish the shrinkage and half-normal priors for general use in models aimed to estimate predictions of the true treatment effect in a future study.</p>
<p>In conclusion, this is the first study to examine the effect of prior distributions for between-study heterogeneity on the predictions from Bayesian binomial random-effects meta-analysis. In Bayesian random-effects meta-analyses aimed to synthesize current evidence only, we support the use of a uniform on τ<sup>2</sup>, but we recommend restricting probability coverage to clinically plausible values. We highly recommend avoiding the inverse gamma prior because of its poor fit, as measured by both RD and PD. Furthermore, if the predictive distribution is of interest, we suggest using PD to investigate model fit and strongly recommend assessing sensitivity to various prior distributions on τ<sup>2</sup>, especially the half-normal on τ<sup>2</sup>, uniform shrinkage on τ<sup>2</sup>, and DuMouchel on τ. These priors are vague but still somewhat informative, conveying more knowledge of between-study heterogeneity and possibly ensuring meaningful predictions of future treatment effects. Consequently, better predictions of future treatment effects could lead to better estimation of the size of a future study. Future research could further evaluate the use of PD as a goodness-of-fit measure in Bayesian meta-analyses that focus on estimations of predictions of future treatment effects.</p>
</sec>
</body>
<back>
<ack>
<p>We thank 2 anonymous reviewers for their valuable comments and suggestions. Dr. O. Gajic-Veljanoski is supported by a Canadian Institutes of Health Research (CIHR) Bisby Postdoctoral Fellowship, Dr. A. M. Cheung is supported by a CIHR/Institute of Gender and Health Senior Scientist Award, and Dr. A. M. Bayoumi holds a CIHR/Ontario Ministry of Health and Long-term Care Applied Chair in Health Services and Policy Research focusing on Equity in Resource Allocation. This study did not receive any external funding; it was performed to fulfill requirements of a PhD degree in health policy, management, and evaluation (clinical epidemiology field) at the University of Toronto.</p>
</ack>
<fn-group>
<fn fn-type="presented-at">
<p>This article was presented at the 2010 SMDM meeting, 24–27 October 2010, Toronto, Canada.</p>
</fn>
<fn fn-type="other">
<p>The online appendix for this article is available on the <italic>Medical Decision Making</italic> Web site at <ext-link ext-link-type="uri" xlink:href="http://mdm.sagepub.com/supplemental">http://mdm.sagepub.com/supplemental</ext-link>.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0272989X12453504">
<label>1.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name>
<name><surname>Abrams</surname><given-names>KR</given-names></name>
<name><surname>Myles</surname><given-names>JP</given-names></name>
</person-group>. <article-title>Bayesian Approaches to Clinical Trials and Health-Care Evaluation</article-title>. <publisher-loc>Chichester, UK</publisher-loc>: <publisher-name>John Wiley &amp; Sons</publisher-name>; <year>2004</year>.</citation>
</ref>
<ref id="bibr2-0272989X12453504">
<label>2.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Borenstein</surname><given-names>M</given-names></name>
<name><surname>Hedges</surname><given-names>LV</given-names></name>
<name><surname>Higgins</surname><given-names>JPT</given-names></name>
<name><surname>Rothstein</surname><given-names>HR</given-names></name>
</person-group>. <article-title>Introduction to Meta-Analysis</article-title>. <publisher-loc>Chichester, UK</publisher-loc>: <publisher-name>John Wiley &amp; Sons</publisher-name>; <year>2009</year>.</citation>
</ref>
<ref id="bibr3-0272989X12453504">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Higgins</surname><given-names>JP</given-names></name>
<name><surname>Thompson</surname><given-names>SG</given-names></name>
<name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>A re-evaluation of random-effects meta-analysis</article-title>. <source>J R Stat Soc Ser A Stat Soc</source>. <year>2009</year>;<volume>172</volume>(<issue>1</issue>):<fpage>137</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr4-0272989X12453504">
<label>4.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Sutton</surname><given-names>AJ</given-names></name>
<name><surname>Abrams</surname><given-names>KR</given-names></name>
<name><surname>Jones</surname><given-names>DR</given-names></name>
<name><surname>Sheldon</surname><given-names>TA</given-names></name>
<name><surname>Song</surname><given-names>F</given-names></name>
</person-group>. <article-title>Methods for Meta-analysis in Medical Research</article-title>. <publisher-loc>Chichester, UK</publisher-loc>: <publisher-name>John Wiley &amp; Sons</publisher-name>; <year>2000</year>.</citation>
</ref>
<ref id="bibr5-0272989X12453504">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Riley</surname><given-names>RD</given-names></name>
<name><surname>Higgins</surname><given-names>JP</given-names></name>
<name><surname>Deeks</surname><given-names>JJ</given-names></name>
</person-group>. <article-title>Interpretation of random effects meta-analyses</article-title>. <source>BMJ</source>. <year>2011</year>;<volume>342</volume>:<fpage>d549</fpage>.</citation>
</ref>
<ref id="bibr6-0272989X12453504">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ades</surname><given-names>AE</given-names></name>
<name><surname>Lu</surname><given-names>G</given-names></name>
<name><surname>Higgins</surname><given-names>JP</given-names></name>
</person-group>. <article-title>The interpretation of random-effects meta-analysis in decision models</article-title>. <source>Med Decis Making</source>. <year>2005</year>;<volume>25</volume>(<issue>6</issue>):<fpage>646</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr7-0272989X12453504">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ades</surname><given-names>AE</given-names></name>
<name><surname>Welton</surname><given-names>NJ</given-names></name>
<name><surname>Caldwell</surname><given-names>D</given-names></name>
<name><surname>Price</surname><given-names>M</given-names></name>
<name><surname>Goubar</surname><given-names>A</given-names></name>
<name><surname>Lu</surname><given-names>G</given-names></name>
</person-group>. <article-title>Multiparameter evidence synthesis in epidemiology and medical decision-making</article-title>. <source>J Health Serv Res Policy</source>. <year>2008</year>;<volume>13</volume>(<supplement>Suppl. 3</supplement>):<fpage>12</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr8-0272989X12453504">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Claxton</surname><given-names>K</given-names></name>
</person-group>. <article-title>The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies</article-title>. <source>J Health Econ</source>. <year>1999</year>;<volume>18</volume>(<issue>3</issue>):<fpage>341</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr9-0272989X12453504">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Claxton</surname><given-names>K</given-names></name>
<name><surname>Thompson</surname><given-names>KM</given-names></name>
</person-group>. <article-title>A dynamic programming approach to the efficient design of clinical trials</article-title>. <source>J Health Econ</source>. <year>2001</year>;<volume>20</volume>(<issue>5</issue>):<fpage>797</fpage>–<lpage>822</lpage>.</citation>
</ref>
<ref id="bibr10-0272989X12453504">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Willan</surname><given-names>AR</given-names></name>
<name><surname>Eckermann</surname><given-names>S</given-names></name>
</person-group>. <article-title>Accounting for between-study variation in incremental net benefit in value of information methodology</article-title>. <source>Health Econ.</source> <month>Sep</month> <year>2011</year>. doi: <pub-id pub-id-type="doi">10.1002/hec.1781</pub-id> [Epub ahead of print].</citation>
</ref>
<ref id="bibr11-0272989X12453504">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Welton</surname><given-names>N</given-names></name>
<name><surname>Ades</surname><given-names>AE</given-names></name>
</person-group>. <article-title>Research decisions in the face of heterogeneity: what can a new study tell us?</article-title> <source>Health Econ</source> <year>2011</year>. <source>Sep</source><year>2011</year>. doi: <pub-id pub-id-type="doi">10.1002/hec.1797</pub-id> [Epub ahead of print].</citation>
</ref>
<ref id="bibr12-0272989X12453504">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wijeysundera</surname><given-names>DN</given-names></name>
<name><surname>Austin</surname><given-names>PC</given-names></name>
<name><surname>Hux</surname><given-names>JE</given-names></name>
<name><surname>Beattie</surname><given-names>WS</given-names></name>
<name><surname>Laupacis</surname><given-names>A</given-names></name>
</person-group>. <article-title>Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials</article-title>. <source>J Clin Epidemiol</source>. <year>2009</year>;<volume>62</volume>(<issue>1</issue>):<fpage>13</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr13-0272989X12453504">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kass</surname><given-names>RE</given-names></name>
<name><surname>Wasserman</surname><given-names>L</given-names></name>
</person-group>. <article-title>The selection of prior distributions by formal rules</article-title>. <source>J Am Stat Assoc</source>. <year>1996</year>;<volume>91</volume>:<fpage>1343</fpage>–<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr14-0272989X12453504">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lambert</surname><given-names>PC</given-names></name>
<name><surname>Sutton</surname><given-names>AJ</given-names></name>
<name><surname>Burton</surname><given-names>PR</given-names></name>
<name><surname>Abrams</surname><given-names>KR</given-names></name>
<name><surname>Jones</surname><given-names>DR</given-names></name>
</person-group>. <article-title>How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS</article-title>. <source>Stat Med</source>. <year>2005</year>;<volume>24</volume>(<issue>15</issue>):<fpage>2401</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr15-0272989X12453504">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gelman</surname><given-names>A</given-names></name>
</person-group>. <article-title>Prior distributions for variance parameters in hierarchical models</article-title>. <source>Bayesian Analysis</source>. <year>2006</year>;<volume>1</volume>(<issue>3</issue>):<fpage>515</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr16-0272989X12453504">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pullenayegum</surname><given-names>E</given-names></name>
</person-group>. <article-title>An informed reference prior for between-study heterogeneity in meta-analyses of binary outcomes</article-title>. <source>Stat Med</source>. <year>2011</year>;<volume>30</volume>(<issue>26</issue>):<fpage>3082</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr17-0272989X12453504">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ades</surname><given-names>AE</given-names></name>
</person-group>. <article-title>ISPOR states its position on network meta-analysis</article-title>. <source>Value Health</source>. <year>2011</year>;<volume>14</volume>(<issue>4</issue>):<fpage>414</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr18-0272989X12453504">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bohning</surname><given-names>D</given-names></name>
<name><surname>Malzahn</surname><given-names>U</given-names></name>
<name><surname>Dietz</surname><given-names>E</given-names></name>
<name><surname>Schlattmann</surname><given-names>P</given-names></name>
<name><surname>Viwatwongkasem</surname><given-names>C</given-names></name>
<name><surname>Biggeri</surname><given-names>A</given-names></name>
</person-group>. <article-title>Some general points in estimating heterogeneity variance with the DerSimonian-Laird estimator</article-title>. <source>Biostatistics</source>. <year>2002</year>;<volume>3</volume>(<issue>4</issue>):<fpage>445</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr19-0272989X12453504">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Colditz</surname><given-names>GA</given-names></name>
<name><surname>Burdick</surname><given-names>E</given-names></name>
<name><surname>Mosteller</surname><given-names>F</given-names></name>
</person-group>. <article-title>Heterogeneity in meta-analysis of data from epidemiologic studies: a commentary</article-title>. <source>Am J Epidemiol</source>. <year>1995</year>;<volume>142</volume>(<issue>4</issue>):<fpage>371</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr20-0272989X12453504">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Higgins</surname><given-names>JP</given-names></name>
<name><surname>Thompson</surname><given-names>SG</given-names></name>
</person-group>. <article-title>Quantifying heterogeneity in a meta-analysis</article-title>. <source>Stat Med</source>. <year>2002</year>;<volume>21</volume>(<issue>11</issue>):<fpage>1539</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr21-0272989X12453504">
<label>21.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Avenell</surname><given-names>A</given-names></name>
<name><surname>Gillespie</surname><given-names>WJ</given-names></name>
<name><surname>Gillespie</surname><given-names>LD</given-names></name>
<name><surname>O’Connell</surname><given-names>D</given-names></name>
</person-group>. <article-title>Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2009</year>;(<issue>2</issue>):<fpage>CD000227</fpage>. Available at: URL: <ext-link ext-link-type="uri" xlink:href="http://www2.cochrane.org/%20reviews/en/ab000227.html">http://www2.cochrane.org/ reviews/en/ab000227.html</ext-link></citation>
</ref>
<ref id="bibr22-0272989X12453504">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bischoff-Ferrari</surname><given-names>HA</given-names></name>
<name><surname>Willett</surname><given-names>WC</given-names></name>
<name><surname>Wong</surname><given-names>JB</given-names></name>
<name><surname>Giovannucci</surname><given-names>E</given-names></name>
<name><surname>Dietrich</surname><given-names>T</given-names></name>
<name><surname>wson-Hughes</surname><given-names>B</given-names></name>
</person-group>. <article-title>Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials</article-title>. <source>JAMA</source>. <year>2005</year>;<volume>293</volume>(<issue>18</issue>):<fpage>2257</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr23-0272989X12453504">
<label>23.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Spinks</surname><given-names>A</given-names></name>
<name><surname>Glasziou</surname><given-names>PP</given-names></name>
<name><surname>Del Mar</surname><given-names>CB</given-names></name>
</person-group>. <article-title>Antibiotics for sore throat</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2006</year>;(<issue>4</issue>):<fpage>CD000023</fpage>. Available at: URL: <ext-link ext-link-type="uri" xlink:href="http://www2.cochrane.org/reviews/en%20/%20ab000023.html">http://www2.cochrane.org/reviews/en / ab000023.html</ext-link></citation>
</ref>
<ref id="bibr24-0272989X12453504">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cranney</surname><given-names>A</given-names></name>
<name><surname>Horsley</surname><given-names>T</given-names></name>
<name><surname>O’Donnell</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Effectiveness and safety of vitamin D in relation to bone health</article-title>. <source>Evid Rep Technol Assess (Full Rep)</source>. <year>2007</year>;(<issue>158</issue>):<fpage>1</fpage>–<lpage>235</lpage>.</citation>
</ref>
<ref id="bibr25-0272989X12453504">
<label>25.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>MacLennan</surname><given-names>AHBJL</given-names></name>
<name><surname>Lester</surname><given-names>S</given-names></name>
<name><surname>Moore</surname><given-names>V</given-names></name>
</person-group>. <article-title>The effect of oral oestrogen and combined oestrogen/progesterone therapy versus placebo for hot flushes</article-title>. <source>Cochrane Database Syst Rev.</source> <volume>2004</volume>(<issue>4</issue>):<fpage>CD002978</fpage>. Available at: URL: <ext-link ext-link-type="uri" xlink:href="http://www2.cochrane.org/reviews/en/%20ab002978.html">http://www2.cochrane.org/reviews/en/ ab002978.html</ext-link></citation>
</ref>
<ref id="bibr26-0272989X12453504">
<label>26.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name>
<name><surname>Abrams</surname><given-names>KR</given-names></name>
<name><surname>Myles</surname><given-names>JP</given-names></name>
</person-group>. <article-title>Prior distributions</article-title>. In: <person-group person-group-type="editor">
<name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name>
<name><surname>Abrams</surname><given-names>KR</given-names></name>
<name><surname>Myles</surname><given-names>JP</given-names></name>
</person-group>, eds. <source>Bayesian Approaches to Clinical Trials and Health-Care Evaluation</source>. <publisher-loc>Chichester, UK</publisher-loc>: <publisher-name>John Wiley &amp; Sons</publisher-name>; <volume>2004</volume>:<fpage>139</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr27-0272989X12453504">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ades</surname><given-names>AE</given-names></name>
<name><surname>Cliffe</surname><given-names>S</given-names></name>
</person-group>. <article-title>Markov chain Monte Carlo estimation of a multiparameter decision model: consistency of evidence and the accurate assessment of uncertainty</article-title>. <source>Med Decis Making</source>. <year>2002</year>;<volume>22</volume>(<issue>4</issue>):<fpage>359</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr28-0272989X12453504">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name>
<name><surname>Best</surname><given-names>NG</given-names></name>
<name><surname>Carlin</surname><given-names>BP</given-names></name>
<name><surname>van der Linde</surname><given-names>A</given-names></name>
</person-group>. <article-title>Bayesian measures of model complexity and fit</article-title>. <source>J R Stat Soc B</source>. <year>2002</year>;<volume>64</volume>(<issue>4</issue>):<fpage>583</fpage>–<lpage>639</lpage>.</citation>
</ref>
<ref id="bibr29-0272989X12453504">
<label>29.</label>
<citation citation-type="web">
<article-title>DIC: Deviance Information Criterion</article-title>. Available from: URL: <ext-link ext-link-type="uri" xlink:href="http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/dicpage.shtml#q1">http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/dicpage.shtml#q1</ext-link>. <access-date>Accessed 13 October 2011</access-date>.</citation>
</ref>
<ref id="bibr30-0272989X12453504">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harrell</surname><given-names>FE</given-names><suffix>Jr.</suffix></name>
<name><surname>Lee</surname><given-names>KL</given-names></name>
<name><surname>Mark</surname><given-names>DB</given-names></name>
</person-group>. <article-title>Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors</article-title>. <source>Stat Med</source>. <year>1996</year>;<volume>15</volume>(<issue>4</issue>):<fpage>361</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr31-0272989X12453504">
<label>31.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Kleinbaum</surname><given-names>DG</given-names></name>
<name><surname>Kupper</surname><given-names>LL</given-names></name>
<name><surname>Muller</surname><given-names>KE</given-names></name>
<name><surname>Nizam</surname><given-names>A</given-names></name>
</person-group>. <article-title>Applied Regression Analysis and Other Multivariable Methods</article-title>. <edition>3rd ed.</edition> <publisher-loc>Pacific Grove, CA</publisher-loc>: <publisher-name>Brooks/Cole</publisher-name>; <year>1998</year>.</citation>
</ref>
<ref id="bibr32-0272989X12453504">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steyerberg</surname><given-names>EW</given-names></name>
<name><surname>Harrell</surname><given-names>FE</given-names><suffix>Jr.</suffix></name>
<name><surname>Borsboom</surname><given-names>GJ</given-names></name>
<name><surname>Eijkemans</surname><given-names>MJ</given-names></name>
<name><surname>Vergouwe</surname><given-names>Y</given-names></name>
<name><surname>Habbema</surname><given-names>JD</given-names></name>
</person-group>. <article-title>Internal validation of predictive models: efficiency of some procedures for logistic regression analysis</article-title>. <source>J Clin Epidemiol</source>. <year>2001</year>;<volume>54</volume>(<issue>8</issue>):<fpage>774</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr33-0272989X12453504">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ades</surname><given-names>AE</given-names></name>
</person-group>. <article-title>A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence</article-title>. <source>Stat Med</source>. <year>2003</year>;<volume>22</volume>(<issue>19</issue>):<fpage>2995</fpage>–<lpage>3016</lpage>.</citation>
</ref>
<ref id="bibr34-0272989X12453504">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marshall</surname><given-names>EC</given-names></name>
<name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>Approximate cross-validatory predictive checks in disease mapping models</article-title>. <source>Stat Med</source>. <year>2003</year>;<volume>22</volume>(<issue>10</issue>):<fpage>1649</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr35-0272989X12453504">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lunn</surname><given-names>DJ</given-names></name>
<name><surname>Thomas</surname><given-names>A</given-names></name>
<name><surname>Best</surname><given-names>N</given-names></name>
<name><surname>Spiegelhalter</surname><given-names>D</given-names></name>
</person-group>. <article-title>WinBUGS—a Bayesian modelling framework: concepts, structure, and extensibility</article-title>. <source>Stat Comput</source>. <year>2000</year>;<volume>10</volume>:<fpage>325</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr36-0272989X12453504">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brooks</surname><given-names>S</given-names></name>
<name><surname>Gelman</surname><given-names>A</given-names></name>
</person-group>. <article-title>Alternative methods for monitoring convergence of iterative simulations</article-title>. <source>J Comput Graph Stat</source>. <year>1998</year>;<volume>7</volume>:<fpage>434</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr37-0272989X12453504">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Daniels</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>A prior for the variance in hierarchical models</article-title>. <source>Can J Stat</source>. <year>1999</year>;<volume>27</volume>(<issue>3</issue>):<fpage>569</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr38-0272989X12453504">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Senn</surname><given-names>S</given-names></name>
</person-group>. <article-title>Trying to be precise about vagueness</article-title>. <source>Stat Med</source>. <year>2007</year>;<volume>26</volume>(<issue>7</issue>):<fpage>1417</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr39-0272989X12453504">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Farrell</surname><given-names>PJ</given-names></name>
<name><surname>MacGibbon</surname><given-names>BTTJ</given-names></name>
</person-group>. <article-title>Protection against outliers in empirical Bayes estimation</article-title>. <source>Can J Stat</source>. <year>1994</year>;<volume>22</volume>(<issue>3</issue>):<fpage>365</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr40-0272989X12453504">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Hagan</surname><given-names>A</given-names></name>
<name><surname>Stevens</surname><given-names>JW</given-names></name>
</person-group>. <article-title>Bayesian assessment of sample size for clinical trials of cost-effectiveness</article-title>. <source>Med Decis Making</source>. <year>2001</year>;<volume>21</volume>(<issue>3</issue>):<fpage>219</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr41-0272989X12453504">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Hagan</surname><given-names>A</given-names></name>
</person-group>. <article-title>Science, Subjectivity and software (comment on articles by Berger and by Goldstein)</article-title>. <source>Bayesian Analysis</source>. <year>2006</year>;<volume>1</volume>(<issue>2</issue>):<fpage>445</fpage>–<lpage>50</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>